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ABSTRACT
Cardiovascular diseases (CVDs) are the leading cause of death globally. An
estimated 17.9 million people died from CVDs in 2016, with ~840,000 of them in the
United States alone. Traditional risk factors, such as smoking, hypertension, and diabetes,
are well discussed. In recent years, chronic kidney disease (CKD) has emerged as a risk
factor of equal importance. Patients with mild-to-moderate CKD are much more likely to
develop and die from CVDs than progress to end-stage renal failure. Vascular calcification
(VC), typical in aging, several genetic and metabolic disorders, is now recognized as a
strong and independent predictor of cardiovascular events and mortality, not only in
diabetic and CKD patients, even in the general population. VC is classified into two distinct
types based on location in the vessel wall; intimal and medial. Elastin-associated medial
arterial calcification (CKD) is more specific to CKD and contributes significantly to
cardiovascular mortality in these patients. It is responsible for loss of vessel elasticity,
increased arterial stiffness, increased pulse pressures and systolic blood pressure, and left
ventricular hypertrophy ultimately causing arrhythmias and heart failure.
Current clinical practice is mostly focused on prevention and retardation of VC
progression. Unfortunately, most patients with CKD remain underdiagnosed, and those
diagnosed have already heavily calcified vessels. As such, they are undertreated since
preventative strategies no longer work at this stage. Unfortunately, there is no FDAapproved treatment available that reverses calcification in countless CKD patients. A
treatment strategy which promotes resorption of calcified lesions, while simultaneously
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avoiding demineralization from normally calcified tissues (i.e., bones and teeth) remains
an urgent health care need. Chelating agents bind to metal cations, can dissolve and “wash
away” calcium deposits if delivered in close proximity to the calcification sites.
This work was undertaken to see if we can develop targeted therapies to deliver chelating
agents to vascular calcification sites. Amongst chelating agents known for their affinity to
Calcium ions (Ca2+), we found that EDTA chelates Ca2+ from hydroxyapatite better than
others. In our laboratory, we have developed a unique targeting mechanism by using
nanoparticles to deliver chelating agents and other drugs to degraded elastin, a
characteristic feature of VC. We take this approach forward in clinically relevant animal
models of CKD.
First, we tested the targeted nanoparticle-based EDTA chelation therapy in a rat
model of adenine-induced renal failure. The targeted nanoparticles delivered EDTA at the
sites of vascular calcification and reversed mineral deposition without any side effects.
Furthermore, we validated the adenine-CKD model in mice to monitor MAC in vivo and
explore the phenotypic and functional alterations associated with it. We were able to target
our nanoparticles to calcified arteries in these mice. The mouse model will help us to test
whether our EDTA chelation therapy tangibly improves arterial function by restoring
vascular health. Lastly, we investigated the possibility of using an ex vivo organ culture
model of VC as a simpler, and relatively easier model to assess if EDTA chelation therapy
promotes vessel homeostasis. The work presented here represents another major step
forward towards the development of targeted EDTA chelation therapy as an
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unconventional therapeutic approach to reverse pathological calcifications in CKD
patients.
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INTRODUCTION

Cardiovascular diseases (CVDs) refer to several types of conditions that affect the
cardiovascular system – heart and blood vessels. CVDs remain the leading cause of death,
being responsible for ~17.9 (31%) million deaths globally, and 840,000 (1 in 3) deaths in
the United States alone [1, 2]. CVD is an umbrella term for many diseases, including blood
vessel disease, heart valve diseases, heart rhythm problems, heart muscle diseases, and
congenital heart diseases, among others. CVDs are often caused by key risk factors such
as high blood pressure, high cholesterol, and habitual smoking and at least one of these risk
factors are present in about half (49%) of the American population [3]. Certain medical
conditions and poor lifestyle choices which are also considered as risk factors include age,
sex, physical inactivity, excessive alcohol use, unhealthy diet, obesity, genetic
predisposition and family history of CVDs, diabetes mellitus and chronic kidney disease
(CKD) [4-6].
CKD, also known as chronic renal failure (CRF) is a condition characterized by
gradual damage to and loss of kidney function over time. As the primary function of the
kidneys is to filter extra water and wastes out of our blood, damage to kidneys causes
wastes to build up in the body resulting in complications such as high blood pressure,
anemia, weakening of bones, poor nutritional health, etc. The two major causes of CKD
are diabetes and high blood pressure, being responsible for up to 2/3rd of cases. Other
diseases and conditions that cause CKD include glomerulo nephritis, polycystic kidney
disease, lupus, prolonged obstruction of the urinary tract, vesicoureteral reflux, and more.
1

Since CKD and CVDs share two major risk factors – diabetes and high blood pressure –
patients with CKD are a group at high risk for developing CVD and cardiovascular events
[5]. Concomitantly, heart diseases represent the most common cause of death amongst
people with CKD and undergoing dialysis. The prevalence and burden of CVD only rises
with declining kidney function.
Ectopic calcification has been observed in many CVDs and is recognized as a
contributing risk factor for cardiovascular events including heart failure, pulmonary
hypertension, and even death in CKD patients. Based on location, calcifications in CKD
can be classified into calcifications of vessels viz. atherosclerotic intimal calcification
(AIC) and medial arterial calcification in large and elastic arteries (MAC), calcification of
heart valves and calcific uremic arteriolopathy (CUA). CKD patients may develop both
types of vascular calcifications, elastin-associated MAC is more specific to CKD; In fact,
in pediatric patients, it is the only form of vessel calcification seen.
Current treatment methods have been limited to preventing and retarding the
progression of calcification. Notably, as yet, there is no consensus about screening for and
intervening to retard the progress of VC and even the most dramatic interventions such as
intense dialyses and renal replacement, make it clear that manifested vessel calcification
cannot be removed. A few options to treat vascular calcifications are surgical methods like
directional atherectomy to physically remove the mineral deposits and placement of stent
grafts to keep the artery open [7, 8]. They are quite invasive and detrimental. A large
number of patients as such remain underdiagnosed and those diagnosed have already
calcified arteries. Therefore, they remain undertreated since preventative strategies can no
2

longer work at this stage. There is a dire need of an alternative pharmacological approach
that promotes reversal of VC by resorption of calcified lesions without detrimental
demineralization in normal tissues (i.e., bones and teeth).
Chelation therapy has been long investigated for reversal of atherosclerotic
calcification. This process typically involves an injection of disodium ethylene diamine
tetraacetic acid (EDTA), a synthetic chemical that binds, or chelates ionic calcium, trace
elements, and other divalent cations [9]. Systemic chelation therapy requires high dosages
of EDTA to be injected, which may result in unwanted side effects such as hypocalcemia,
renal toxicity, and loss of mineral from bone [10, 11]. In our laboratory, we have developed
a unique method to deliver chelating agents, and other therapeutics, in a site-specific
manner to vascular calcification sites through targeted nanoparticles (NPs). Further, we
have shown that such targeted delivery of EDTA through use of albumin NPs to a calcified
site, reverses experimentally created vessel calcification while avoiding untoward side
effects of systemic therapy.
In this dissertation, we take this approach forward in a clinically relevant animal
model of CKD. We have studied the efficacy of targeted EDTA chelation therapy in a
dietary adenine model of renal failure in rats. We also explored the feasibility of using
targeted EDTA chelation therapy in a mouse model of dietary adenine which would serve
as an aid in the near future to investigate if reversal of arterial calcification improves
vascular homeostasis through the use of cell-lineage tracing. Additionally, we examined if
removal of calcification by EDTA chelation therapy can reverse the associated phenotypic
changes of vascular smooth muscle cells (VSMCs) in an organ culture model of porcine
3

carotid arteries. Overall, our goal was to present targeted EDTA chelation as an excellent
alternative therapeutic approach to reverse MAC clinically.
The dissertation is organized as follows:
•

In Chapter 2, we present a comprehensive review of:
→ Cardiovascular System: Cardiovascular diseases, cardiovascular
system, and structure of the aortic wall.
→ Elastin: Structure, function, ultrastructure, mechanism of elastin
synthesis and elastic fiber assembly, and elastin degradation in disease.
→ CKD: Definition, classifications, consequences, and cardiovascular
complications in CKD.
→ VC: Types, mechanisms, and current treatment strategies.
→ Animal models of VC: In vivo studies with animal models of VC, CKD
and MAC, and adenine-induced CKD model of VC.
→ Chelation Therapy: Definition, history of chelation therapy, types of
chelating agents used, EDTA chelation therapy, clinical trials with
EDTA chelation therapy.
→ Targeted EDTA chelation therapy: Nanoparticles as drug delivery
agents, albumin nanoparticles, targeting of albumin nanoparticles to
degraded elastin in calcification.

•

Chapter 3 provides rationale for this research and specific aims designed for

this project.
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•

In Chapter 4, we compare three different chelating agents – EDTA, EGTA,

and BAPTA to deduce the best chelator for use in targeted chelation therapy
•

In Chapter 5, we discuss whether EDTA, a chelating agent, loaded and

elastin-antibody conjugated nanoparticles can be targeted to sites of elastin-specific
medial arterial calcification for its reversal in a rat chronic kidney disease model.
•

In Chapter 6, we demonstrate targeting of elastin-antibody conjugated

albumin nanoparticles to sites of medial arterial calcification in a mouse adenine
model of CKD-induced calcification. Monitoring of disease progression in vivo and
VSMC cell status were explored for the potential use of this model to investigate
whether reversal of MAC through targeted EDTA chelation therapy can restore
vascular homeostasis.
•

In Chapter 7 we explore the feasibility of an ex vivo organ culture model of

porcine carotid arteries to better understand the mechanism of VC and direction of
VSMC before and after treatment with EDTA-loaded NPs. The ex vivo model may
serve as a bridge between cell culture and extensive animal models currently in use
to provide complementary information about intrinsic mechanisms and treatment
of VC.
•

Chapter 8 summarizes and lists conclusions from the present research and

provide future recommendations to take this research forward and take major steps
towards clinical translation of targeted EDTA chelation therapy for permanent
reversal of VC.

5
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REVIEW OF LITERATURE

Cardiovascular diseases
Cardiovascular diseases (CVDs) are the number one cause of death globally; more
people die annually from CVDs than of any other cause. An estimated 17.9 million people
died globally from CVDs in 2016, representing approximately 30% of all registered deaths
[1]. Out of the 17 million premature deaths due to non-communicable diseases in 2015,
82% are in low- and middle-income countries, and 37% of them are caused by CVDs [2].
In the United States alone, CVDs have remained the leading cause of death, responsible
for as many as 840, 000 deaths in 2016. The annual total cost of CVDs in the US has been
estimated at $351.2 billion in 2014-15 [12].
The term CVDs describe a range of conditions that affect the cardiovascular system
– heart and blood vessels. They are grouped into disorders of the blood vessels, such as
coronary artery disease, cerebrovascular disease, peripheral arterial disease, arterial
calcification, abdominal aortic aneurysms (AAAs), deep vein thrombosis and pulmonary
embolism; disorders of the heart structure and muscle, including congenital heart disease,
rheumatic heart disease, carditis and cardiomyopathy; problems with heart rhythms known
as arrhythmia; and disease of the heart valves, like calcification of the heart valves, valve
prolapse and stenosis.

6

Figure 2-1: Global map, age-standardized death rate of CVD in 2015 [13].

Figure 2-2: Heart disease death rates across the US [14].

7

Figure 2-3: Types of Cardiovascular Diseases [15].

Risk factors for CVDs are classified as non-modifiable and modifiable. Nonmodifiable risk factors are age, gender, ethnic background, socioeconomic status, and
familial history of the disease. Physical inactivity, excessive tobacco use and alcohol
consumption, unhealthy diet resulting in high cholesterol levels and obesity, uncontrolled
blood pressure come under modifiable risk factors [3, 4, 16]. With better lifestyle choices,
modifiable risk factors can be kept under check and reduce chances of having CVDs. Heart
failure is the most common, costly, and potentially fatal outcome of many of the CVDs
[17].

8

The Cardiovascular System
The Cardiovascular System (Figure 1-4), also known as the circulatory system,
functions to carry blood through vessels to and from all parts of the body. It is a closed
tubular system in which the blood is propelled by a principal muscular organ called the
heart. There are two major circuits in the circulatory system, the systemic and the
pulmonary, both made up of vessels viz., arteries, veins and capillaries [18].

Figure 2-4: The human cardiovascular system (simplified). Red indicates oxygenated
blood in the arteries, blue indicates deoxygenated blood in veins [18].

9

A third circuit known as the lymphatic system, whose primary function is to
transport lymph, is also considered part of the circulation and helps the body to get rid of
toxins, waste and other unwanted materials. Blood vessels vary with size and function,
but all of them possess the same basic structure. Each type of vessel has a lumen - a hollow
passageway through which the blood flows and is surrounded by the vessel wall. The vessel
wall has three layers, or tunics, meaning “coats” in Latin.

Figure
2-5:
Structure
of
Blood
Vessels.
(a)
(b) veins, and (c) Micrograph showing relative differences in thickness [19].
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Arteries,

The deepest layer, tunica intima, is lined by a specialized simple squamous
epithelium known as endothelium. The middle layer, tunica media, is the thickest of the
layers in arteries. It is rich in smooth muscle supported by connective tissue mainly made
up of elastic fibers arranged in circular sheets. The outer layer is the tunica adventitia (this
is the thickest layer in the veins) and is entirely made of connective tissue primarily
composed of collagenous fibers and nerves that supply the vessel as well as the nutrient
capillaries (called vasa vasorum) in the larger blood vessels.
Arteries carry blood from the heart to various organs and can be further
subcategorized by their size. All arteries, as mentioned above have relatively thick walls
that can withstand the high pressure of blood ejected from the heart. Those closest to the
heart have the thickest walls, containing a high percentage of elastic fibers throughout the
wall. These type of arteries are elastic arteries and are typically >10mm in diameter. Further
from the heart, where the blood surge is stifled, the percentage of elastic fibers decreases,
and there is increased smooth muscle in the medial layer. These are the muscular arteries
with a diameter range between 0.1mm and 10mm. Muscular arteries branch to distribute
blood to a vast network of arterioles. The transition from artery to arteriole is very gradual,
with progressive thinning of the wall and decreased lumen size (the diameter of an
arteriole is <0.5mm). Overall, the heart forces blood into the arteries, who through their
elastic recoil, send blood on in pulsating waves. Therefore, it is crucial that the arteries
possess strong, elastic walls to ensure fast, efficient blood flow in absence of which there
would be a plethora of vascular complications.
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Elastin Structure and Degradation
Elastin makes up roughly 50% of the arterial extracellular matrix (ECM) as
discussed above and is the most prevalent structural protein. Aside from the arteries, elastin
is present in the ECM of tissues like skin, lungs and renders them elastic properties. With
a half-life period of 74 years, majority of elastin deposition in the body occurs during
embryonic stage and early childhood [20, 21]. It rarely undergoes any remodeling and has
a very low turn-over rate. Synthesis of elastin been well documented in fibroblast cells,
smooth muscle cells, chondrocytes, and endothelial cells [22-25]
Elastin is made up of elastic fibers that have two key components, one amorphous
and one fibrillary. The amorphous component is extensively cross-linked and comprises
90% of the mature fiber. The fibrillar component is a collection of microfibrils that are
roughly 8-16 nm long and rich in acidic glycoproteins [26, 27]. These microfibrils are
located around the periphery of the amorphous content and contain a number of
glycoproteins like microfibril-associated glycoproteins (MAGP-1, -2, -3, -4, fibrillins,
latent TGF-β binding protein (LTBP) and fibulins contribute to anchorage of elastin and
provide its structural coating [28, 29].
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Figure 2-6: TEM of cross section of elastin and fibrillin deposited by rat vascular cells in
culture [30].
The primary structure of elastin is mainly composed of hydrophobic amino acids,
such as glycine and proline [31]. There are a couple of highly conserved peptide sequences
in the elastin fiber – ‘VPGVG’ and ‘PGVGV’. Due to these recurring amino acid residues
(XPGX’ where X and X’ are hydrophobic), elastin is a highly hydrophobic protein [32].
The cellular production, orientation, assembly, crosslinking, and deposition of
elastin is a tightly regulated hierarchical process and is not very well understood.
Tropoelastin, a 72 kDa soluble precursor of mature elastin, is its monomeric form. Human
tropoelastin is encoded by a single gene (ELN) with multiple isoforms and is present as a
single copy on the chromosome-7 [33]. Post translational modification of tropoelastin
results in the mature 60 kDa protein. Tropoelastin gene is expressed during prenatal
development by smooth muscle cells, endothelial cells, and fibroblasts. As we age,
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however, ELN expression decreases dramatically along with decreased elastin production.
In middle-aged people, elastin production is mostly non-existent, and humans rely on
elastin deposition that occurs in the womb and very early in life [34].
The process of elastogenesis is broadly classified into the following stages: (i)
tropoelastin synthesis, (ii) coacervation, (iii) microfibrillar deposition, (iv) crosslinking,
and (v) maturation. In order for a mature elastin fiber to form, tropoelastin molecules must
interact and crosslink with each other. Fibrillin-1 largely makes up the microfibrils in the
ECM that anchor the forming elastic fibers. Lysyl oxidases are a group of five enzymes
including LOX, and LOXL 1-4, which cross-link tropoelastin and aid the process.

Figure 2-7: Illustration of elastin fiber synthesis and assembly [35].
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Initially, the ELN gene is expressed by cells and tropoelastin molecules are secreted
into the ECM. These tropoelastin molecules begin to self-aggregate or coacervate due to
the inherent tendency of tropoelastin to coacervate owing to its excessive hydrophobicity
[36]. The coacervating tropoelastin molecules form ~1µm spherules and remain attached
to the cell surface until their deposition on microfibrils. Elastin binding protein (EBP),
made of a 67 kDa peripheral subunit attached to two membrane-bound proteins of 61 kDa
and 55 kDa MW, carries tropoelastin molecules to fiber formation sites on the surface of
the cell. Tropoelastin initially binds to EBP and forms a stable complex. The 67 kDa
subunit then loses its affinity for tropoelastin and the membrane-bound protein, when a
sugar moiety binds to the EBP. This loss of affinity results in tropoelastin being released
onto growing elastin fibers [26]. The microfibrils in ECM provide a scaffold for directing
and propagating elastin growth and further coacervation and also recruit LOX enzymes for
crosslinking [37-39].
Eventually, tropoelastin is oxidized by LOX enzymes and is followed by aldol
condensation and Schiff base reactions among lysyl residues resulting in crosslinking of
elastin fibers with desmosine and isodesmosine links [40]. The matured elastin produced
as the final product is very stable and gives the tissues their ability to stretch and recoil
[41]. This entire process of elastic fiber assembly is illustrated in Figure 1-7.
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Figure 2-8: Depiction of elastic recoil [42].
One of the consistent features of many vascular diseases is the fragmentation and
degradation of elastic lamina. Elastic lamina degradation is witnessed in vascular
calcification [43, 44], diabetes [45], end-stage renal disease [46, 47], and aortic aneurysm
[48]. Additionally, vascular proliferative diseases affecting smaller arteries like coronary
arterial occlusion and atherosclerotic-mediated stenosis share elastin degradation as a
common pathological feature [49, 50]. In such disease conditions, elastic lamina is
degraded and the amorphous elastin core protein is exposed.
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Chronic Kidney Disease
Chronic Kidney Disease (CKD) is a broad moniker for heterogeneous disorders
affecting kidney structure and function. It is a worldwide public health problem with an
ever-increasing incidence and prevalence, resulting in poor outcomes, and therefore a high
treatment cost [51]. The National Kidney Foundation (NKF), in 2002, published 15 clinical
practice guidelines on evaluation, classification, and risk stratification in CKD. The
definition of CKD has evolved since then, but current international guidelines define this
condition as decreased kidney function as indicated by glomerular filtration rate (GFR) of
less than 60 mL/min per 1.73m2, or kidney damage markers, or both, for a minimum of 3
months [52]. When GFR is found to be less than 15 mL/min per 1.73m2, the patient is
adjudged to have reached end-stage renal disease (ESRD) at which point the kidney is no
longer believed to sustain life over the long term. The burden of CKD is substantial;
According to WHO global health figures, 1.5% of the deaths worldwide were attributed to
CKD in 2012 and it is further projected that the death rate from CKD will continue to
increase to reach 14 per 100,000 people by 2030 [53]. CKD is common among adults in
the US; more than 30 million American adults may have CKD, with its associated diseases
being the 9th leading cause of death [54]. The two primary causes of CKD are diabetes and
hypertension, being responsible for 2/3rd of the cases in high- and middle-income countries
and also low-income countries. Diabetes accounts for 30-50% of all CKD and affects 285
million (6.4%) adults worldwide, and this number is only expected to increase by 69% in
high-income countries and 20% in low-income and middle-income countries by 2030.
Greater than a quarter of the adult worldwide population was estimated to have
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hypertension in 2000, while this proportion is projected to rise by approximately 60% by
2025 [55]. Other conditions that affect the kidneys include glomerulonephritis, inherited
diseases such as polycystic kidney disease, developing malformations, lupus and
obstructions caused by kidney stones, tumors, or enlarged prostate in men. In developing
countries, common causes of CKD may also include glomerular and tubulointerstitial
diseases as a result of infections and exposure to drugs and toxins [56].
A conceptual model for development, progression, and complications of CKD
includes antecedents associated with increased risk, disease stages, and complications
including death. Risks are usually categorized either as susceptibility to kidney disease
because of sociodemographic and genetic factors, or as exposure to factors which would
lead to the disease. It is noted that early stages of diseases are often devoid of symptoms
and detected during assessment for comorbid disorders, and tend to be reversible. Rapidly
progressive diseases, however, can lead to kidney failure within months. Owing to its
importance in the pathophysiology of complications, GFR is used to classify CKD into five
stages: more than 90 mL/min per 1·73 m 2 (stage 1), 60–89 mL/min per 1·73 m 2 (stage
30–59 mL/min per 1·73 m 2 (stage 3), 15–29 mL/min per 1·73 m 2 (stage 4), and less than
15 mL/min per 1·73 m 2 (stage 5).
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Figure 2-9: Conceptual model for chronic kidney disease and its complications [57]

Kidney failure is traditionally considered as the most serious outcome of CKD.
When symptoms are severe, they can be treated only through dialysis or in more serious
cases transplantation. As mentioned above, kidney failure at this stage is known as ESRD.
However, there are several other consequences of CKD that include not only renal
dysfunction and progressive renal failure but also complications of decreased kidney
function and increased risk of cardiovascular disease. Additional complications include
acute kidney injury, infection, cognitive impairment, and diminished physical function [5863]. All these complications contribute to high morbidity and mortality and in general,
poor quality of life. In patients with CKD, compared to general population, cardiovascular
diseases (CVDs) are more frequent and severe. It often goes unrecognized and
undertreated, and it is now increasingly apparent that individuals with various stages of
CKD are more likely to die of cardiovascular complications than progress to ESRD. As
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such, these individuals must be viewed as being in the highest risk group for cardiovascular
disease and mortality [64, 65].
Cardiovascular Complications in CKD
CVD also represents the leading cause of mortality in CKD patients, and its
prevalence and burden only increase with declining renal function [66, 67]. Cardiovascular
complications are approximately three times more frequent in patients with CKD than in
other known cardiovascular risk groups, and mortality is 10-fold more frequent in patients
on dialysis than age- and sex-matched non-renal populations. As a matter of fact, patients
with mild to moderate CKD (Stages 1-3 are much more likely to develop and die from
CVD than progress to ESRD. Increased cardiovascular risk in CKD patients is partly
because of traditional risk factors such as diabetes, hypertension, and hyperlipidemia.
However, associations of reduced kidney function with cardiovascular risk are independent
of these traditional risk factors, and they fail to adequately explain the observations made
in these patients.
Non-traditional kidney-specific risk factors make noteworthy contributions to
cardiovascular risk in these cases. Some of these non-traditional factors that play a role in
the

association

of

renal

failure

and

CVD

include

anemia,

hypervolemia,

hyperphosphatemia, endothelial dysfunction, nitric oxide bioavailability, Asymmetric
dimethylarginine (ADMA), dyslipidemia, inflammatory and oxidative stress, etc. [68-70].
Apart from left ventricular hypertrophy (LVH), which is present very early in the disease
course even in normotensive CKD patients, structural alterations of the myocardium, as
well as intra-and extra-cardiac blood vessels are hallmarks of this disease.
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Cardiovascular calcifications also become highly prevalent as CKD progresses and
are potent predictors of cardiovascular mortality in these patients [46, 71]. London et al.
demonstrated that the extent and histoanatomic type of vascular calcification are predictors
of subsequent mortality [72]. There are four different manifestations of calcifications in
diseased patients: advanced calcification of the intimal plaques, medial calcification of
large and elastic arteries, calcification of heart valves and myocardium, and a rare condition
known as calcific uremic arteriolopathy (also known as calciphylaxis). All four of them are
distinct yet have overlapping pathological mechanisms [71, 73, 74].

Figure 2-10: Types of cardiovascular calcifications. (A) Atherosclerotic calcification. (B)
Medial calcification. (C) Valvular calcification. (D) Calciphylaxis [75]
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Vascular Calcification
Accelerated vascular calcification is a hallmark of CKD patients and plays a pivotal
role in the CVD burden and eventual mortality in these patients. In patients with late-stage
renal disease, the risk of death linearly correlates with an increase in numbers of sites on
the vasculature affected by calcification; in the aorta, carotid, and femoral arteries [76].

Figure 2-11: Probability of all-cause survival according to calcification score [76]

Types of Vascular Calcification
Two types of calcification are observed in the vasculature, both of which affect
patients with long-standing kidney disease, particularly amongst those on dialysis – medial
arterial calcification (MAC, also known as calcific arteriosclerosis or Monckeberg’s
sclerosis) and accelerated calcification of intimal plaque (also known as calcific
atherosclerosis) [71, 77-79].
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Figure 2-12: Atherosclerotic intimal calcification vs. Medial arterial calcification [80]

Intimal calcification is typically considered the last step in classical atherosclerosis
and is a multifactorial process involving inflammation, macrophage infiltration,
dyslipidemia, and advanced glycation end products (AGEs), etc. On the contrary, medial
calcification is characterized by diffuse mineral deposition circumferentially along or
within elastic lamellae of the medial layer of the arterial wall. It can occur independently
or in conjunction with intimal calcification but is more common among the two in CKD or
diabetic patients [73, 81].

Morphologically, atherosclerotic calcification occurs as

dispersed, spotty, and patchy deposits of calcium in a matured plaque whereas MAC gives
a “tram-line” or “railroad track” like appearance as more and more lengths of the arterial
tree calcify.
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Intimal calcification results in vessel narrowing and dysfunction, possibly causing
a thrombotic event eventually. Atherosclerotic plaque burden is higher, and the lesions
more distinctly calcified in CKD patients compared to normal populations.[82]. MAC, on
the other hand, contributes to loss in vessel elasticity, increased arterial stiffness resulting
in increased pulse pressures, increased systolic blood pressure, and LVH ultimately causing
arrhythmias and heart failure [72]. While patients with CKD can develop both types of VC,
MAC is more specific to CKD; it is the exclusive form of VC observed in pediatric CKD
patients. MAC contributes significantly to cardiovascular mortality in CKD patients [83].

Figure 2-13: Radiographs of intima and media calcification as seen in the pelvis and the
thigh of CKD patients. (A) Intima calcification is seen as discrete plaques with irregular
and patchy distribution. (B &C) Media calcification present as a uniform linear railroad
track. (D) Presence of both, intima and media calcification is reflected as discordances
[72].
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Mechanisms of Vascular Calcification
Calcification of arteries in CKD is a catenation of well-orchestrated and tightly
regulated processes which involve cellular and molecular reprogramming, structural and
functional changes in arterial cells and ECM. Several studies have described key events
required for the initiation and promotion of calcification. An imbalance of calcification
inhibitors and promoters in CKD drives calcification. Loss of inhibitors which tightly
control spontaneous pathological precipitation of calcium – phosphate crystals, such as
Matrix Gla-protein (mGP) [84], Fetuin-A [85], Klotho [86], Pyrophosphate (PPi) [87],
Osteopontin [88], Osteoprotegerin [89] instigates calcification. Transcription factors such
as Runt-related transcription factor (RUNX2, also known as Cbfa1) [90], Muscle segment
homeobox 2 (MSX-2) [91], Bone-morphogenic proteins (BMP-2, 4 and 6), Osteocalcin
(OCN), Alkaline phosphatase (ALP) [92] etc. which are critical for normal bone
development, have been identified at sites of human arterial calcification in both general
and CKD patients [93], in animals and also in vitro. In addition, development of a
calcifiable ECM, induction of apoptosis and vesicle release accompanied by
osteogenic/chondrogenic differentiation of vascular smooth muscle cells (VSMCs) are all
important players which spur active calcification processes [90, 94, 95].
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Table 1-1: List of inhibitors and promoters of vascular calcification in CKD.
Calcification Inhibitors

Calcification Promoters
BMP-2,4 and 6

Matrix Gla-protein

Osteocalcin

Fetuin-A

Alkaline Phosphatase

Klotho

RUNX2

Pyrophosphate

Oxidative Stress

Osteopontin

MMP2, 3 and 7

Osteoprotegerin

SOX9

BMP-7

Ca2+ and PO42Apoptosis/Apoptotic bodies

Although a multitude of mechanisms are involved, ectopic, especially vascular,
calcification in CKD is largely actuated by a dysregulation of mineral metabolism, in
particular Ca and P. Hyperphosphatemia, a result of reduced renal phosphate clearance in
combination with increased Ca X P product level are recognized as chief culprits of
accelerated arterial calcification in CKD patients. Deposition of calcium phosphate salts in
the media of the arteries occurs on the amorphous elastin that makes up the elastic lamellae.
It is augmented in the context of elastin degradation by elastases and other such proteases.
In particular, Matrix metalloproteinases (MMPs) and cathepsins (CTS) have been shown
to be overexpressed and involved in calcified arteries. MMP-2, MMP-9, CTS-K, and CTSL can degrade elastin laminae in the media [96-100].
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Figure 2-14: Mechanism of vascular calcification in chronic kidney disease [94].

Current Treatment Strategies
Therapeutic strategies and inventions that may stabilize and potentially reverse
vascular calcification may be of immense value to patients with CKD. Most of the
treatment methods in use have been limited to optimizing and managing the dysregulated
mineral metabolism and bone turnover diseases, both of which are characteristic to CKD.
It should be noted here that the strong relationship between progressing renal dysfunction
and increased presence and severity of VC means that primary prevention may potentially
have a positive impact on VC. A good number of clinical trials in patients with
hypertension and normal renal function have shown that anti-hypertensive treatments
reduce aortic stiffness [101, 102]. Different classes of antihypertensive drugs may have
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different effects on arterial stiffness. Calcium channel blockers (CCBs), Angiotensinconverting enzyme inhibitors (ACEi), and Mineralocorticoid receptor antagonists
(MCRAs) have a beneficial effect in reducing arterial stiffness and central blood pressure.
The first study in humans to demonstrate an effect of CCBs on VC was a sidearm of the
Nifedipine Study: Intervention as Goal for Hypertension Therapy (INSIGHT). In this
particular study, nifedipine was found to inhibit the progression of coronary calcium in a
sub-group of 201 high-risk hypertensive patients compared to co-amizolide (a diuretic).
However, the exact clinical message of this study is unclear in the light of INSIGHT results
which showed comparable effectiveness of nifedipine and co-amizolide in preventing
overall cardiovascular events [103]. Other studies prior and after have evaluated the effect
of CCBs for their effect on central blood pressure and arterial stiffness [104, 105].
It is now common knowledge that ACEi, Angiotensin receptor blockers (ARBs)
and Aldosterone antagonists interfere with the Renin-Angiotensin-Aldosterone System
(RAAS), and confer benefits on vasculature beyond simply controlling the blood pressure.
The effects of ACE inhibition on coronary plaque progression in humans in relation to its
calcium content have been investigated in a study named PERSPECTIVE. A substudy of
the EUROPA trial, PERSPECTIVE tested the effect of perindopril on coronary plaque.
Only plaques with a calcium score of 0-25% regressed with perindopril in comparison to a
placebo, but plaques with moderate (25-50%) and high (50-100%) calcification progressed
equally as in placebo group [106]. In another study with 478 young type I diabetic patients
having albuminuria, ACEi/ARB treatment significantly lowered CAC progression over
~2.5 years compared to those without any treatment [107]. In a prospective randomized
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trial with 31 patients having essential hypertension and LVH, the effects of combined
therapy of an ARB (Valsartan) and ACEi (Perindopril) were studied and compared with
those of respective monotherapies. The findings suggested that, compared to respective
monotherapies, perindopril, and valsartan together exerted greater favorable effects.
Further, an open randomized trial conducted by Frimodt-Møller M et al. investigated
whether a more complete inhibition of RAAS by combining ACEi (Enalapril) and ARB
(candesartan) compared to monotherapy has an additive benefit in CKD patients. They
found that dual blockade of RAS resulted in additive BP independent reduction in Pulse
wave velocity (PWV) and arterial stiffness compared to monotherapy [108].
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Table 2-2: Primary prevention of vascular calcification
Treatment

Mechanism of
Action/Outcome

References

Primary Prevention – Antihypertensive Drugs

Calcium Channel Blockers
(CCBs)
Nifedipine

Slower progression of
coronary calcification in
patients on nifedipine vs. coamilozide

Motro et al. 2001 [103]

Coronary plaques with no or
little calcium (0-25%)
regressed on perindopril and
not in placebo

Bruining et al. 2009 [106]

Perindopril/Valsartan

ACEi/ARB treatment was
associated with substantially
reduced odds of CAC
progression

Maahs et al. 2006 [107]

Enalapril/Candesartan

Dual blockade of the RAAS
resulted in additive BP
independent reduction in
PWV and arterial stiffness in
CKD patients.

Frimodt-Møller M et al. 2012
[108]

Angiotensin-converting
Enzyme Inhibitors
(ACEi)/Angiotensin Receptor
Blockers (ARBs)
Perindopril
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Beyond primary prevention using antihypertensives, secondary prevention of VC
by correcting hyperphosphatemia and secondary hyperparathyroidism (sHPT), which are
universal consequences of renal failure embodies a central clinical approach. This is
accomplished by oral phosphate binders, active vitamin D compounds, calcimimetics,
adjusting calcium concentration in the dialysate, and surgical correction of sHPT. It is
pertinent to note that phosphate control by dietary restriction to 800-1000 mg/day lowered
urinary phosphate excretion along with a decrease in phosphorus absorption, but the
regimens are notoriously hard, and there is a tendency to relapse. [109].
Oral phosphate binders are the mainstay in the management of serum phosphate
levels in patients undergoing dialysis. These medications bind to phosphate in the gut,
either by forming an insoluble complex or by binding it into a resin and are usually
classified as calcium-containing (Calcium acetate, Calcium carbonate, Calcium
ketoglutarate, etc.) and calcium-free (Magnesium carbonate, Lanthanum carbonate,
Sevelamer hydrochloride, and Sevelamer carbonate, etc.). Although both kinds of
phosphate binders are effective at regulating phosphate levels, the calcium-containing
phosphate binders are hazarded for their concomitant calcium load and its effect on
vascular calcification [110]. In a randomized study with 200 hemodialysis patients treated
with either sevelamer or calcium salts for the treatment of hyperphosphatemia, serum
phosphate was controlled equally with both agents whereas subjects treated with calcium
experienced significant hypercalcemia and intact Parathyroid hormone (PTH) levels.
Moreover, both coronary artery and aortic calcification progressed significantly with
calcium but not with sevelamer (~6 months – 1 year) [111]. A total of 119 patients with no
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evidence of coronary calcification showed little evidence of disease development over the
next 18 months, either on calcium-containing phosphate binders or sevelamer. However,
subjects with a history of at least mild coronary calcification had significant progression at
6, 12, and 18 months following treatment with those on calcium-containing phosphate
binders showing rapid progression [112]. Several prospective studies show an evidently
reduced rate of Coronary artery calcium (CAC) in ESRD patients on sevelamer compared
with those on calcium carbonate or calcium acetate [113].
Ameliorating the effects of sHPT is a vital approach to treat disordered bone and
mineral metabolism. Although high parathyroid hormone itself does not correlate
positively with and may not cause vascular calcification, its management may help in
minimizing hypocalcemia. Management of sHPT is achieved by active vitamin D
compounds, calcimimetics, etc. Vitamin D plays an important role in multiple metabolic
pathways, including regulation of mineral metabolism. Active vitamin D formulations, or
vitamin D receptor activators (VDRAs) including calcitriol, alfacalcidiol, doxercalciferol,
and paracalcitriol have been prescribed in the treatment of sHPT in CKD. Hemodialysis
and peritoneal dialysis patients who received VDRAs experience better survival outcomes
than those who do not, regardless of their PTH levels [114]. Calcitriol, alfacalcidiol, and
doxercalciferol can effectively lower PTH but have the side effect of heightening
gastrointestinal absorption of Ca and P causing an undesirable load [115]. In a 2-year
follow up study in dialysis patients, progress of aortic arch calcification was associated
with higher accumulative doses of alfacalcidiol [116]. Paracalcitriol may preferentially
target the parathyroid gland while avoiding the gastrointestinal effect and thus is less
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associated with VC [117]. Nevertheless, more suitably sized randomized controlled trials
are needed to determine the optimal doses and type of VDRAs to be used in therapy.
Calcimimetics are compounds that mimic the effects of Ca in vivo. They can work
as a treatment for hyperparathyroidism by binding to Calcium sensing receptors (CaSRs)
in the parathyroid glands. By binding to CaSRs, calcimimetics allosterically modulate them
to become more sensitive to existing levels of circulating Ca, and they, in turn, suppress
excess secretion of PTH. The only significant randomized study to assess the effects of
calcimimetics is the ADVANCE study with CINACALCET which showed that along with
the use of VDRA therapy, cinacalcet slowed the progression of VC over VDRA therapy
alone in hemodialysis patients [118]. However, a more recent EVOLVE study reported that
cinacalcet failed to significantly reduce the risk of death or major cardiovascular events in
patients with moderate-to-severe sHPT who were undergoing dialysis [119]. For
progressive, biochemically-severe, and often symptomatic sHPT, surgical removal of a
part of the parathyroid gland, known as parathyroidectomy, may be the treatment of choice.
Subtotal parathyroidectomy has been shown to arrest the progression of CAC in dialysis
patients [120]. In chronic hemodialysis patients who underwent total parathyroidectomy,
retrospective evaluation of prognosis revealed that parathyroidectomy, atrial fibrillation
(AF), and serum albumin were significant factors for total and especially cardiovascular
mortality. Total parathyroidectomy was associated with better survival, probably due to
decreased cardiovascular mortality [121].
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Table 2-3: Secondary prevention strategies against VC.
Treatment

Mechanism of
Action/Outcome

References

Secondary Prevention
Hyperphosphatemia
Dietary Phosphate Control

Reduction of circulatory
phosphate imbalance and
reduced hyperphosphatemia

Phosphate Binders

Secondary
hyperparathyroidism

Vitamin D Receptor
Activators (VDRAs)

Management of sHPT by
minimizing
hyperphosphatemia and
hypocalcemia without
causing hypercalcemia and
overly suppressing PTH

Calcimimetics

Isakova, T., et al. 2011 [109]
Hutchison, A.J., et al. 2011
[110]
Chertow, G.M., et al. 2002
[111]
Block, G.A., et al. 2005 [112]
Russo, D., et al. 2007 [113]

Teng, M., et al. 2003 [114]
Tentori, F., et al. 2006 [115]
Ogawa, T. et al. 2010 [116]
Sprague, S.M., et al. 2003
[117]
Raggi, P., et al. 2011 [118]
Investigators, E.T., et al. 2012
[119]

Parathyroidectomy

Bleyer, A.J., et al. 2005 [120]
Iwamoto, N., et al. 2012
[121]
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In addition to these preventative treatment strategies, there have been several
potential therapies that tried to directly target the calcification process. Pyrophosphate
(PPi) is a powerful inhibitor of calcium crystallization that circulates at sufficient
concentrations so as to prevent hydroxyapatite formation, thus serving as an endogenous
inhibitor of calcification. PPi may be deficient in advanced renal failure and plasma levels
of PPi may be reduced in dialysis patients. In general, an inverse association of PPi
concentrations is seen with VC in CKD and ESRD patients [87]. Humans lacking
ectonucleotide pyrophosphorylase (Enpp1), the enzyme that synthesizes extracellular PPi,
are also known to develop several MAC at an early age. However, rapid hydrolysis of PPi
in vivo limits this therapy and in turn prompted the development and use of
nonhydrolyzable analogs, known as bisphosphonates.
Studies, although small, with etidronate show a beneficial effect in CKD and ESRD
patients. In a study with a mean patient age of 63.2±8.2 and mean duration of dialysis of
7.4±5.5, 35 patients were administered etidronate for 14 days over three cycles. CAC
progression in these patients was significantly less pronounced during treatment than
compared to the period before treatment was initiated [122]. In another study with
etidronate, patients with ESRD and undergoing dialysis three times per week were given
etidronate orally for 23 months. Aortic calcification area (ACA) in these patients did not
change over 23 months, but the control group had significantly elevated ACA scores [123].
Calcification scores of the coronary arteries, thoracic, and abdominal aorta collected by a
multi-detector-row CT scanner showed that etidronic acid markedly reduced aortic
calcification in patients with ESRD undergoing chronic hemodialysis [124]. There is still
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a debate over efficiency of bisphosphonate therapy, and results differ by the agent in
question; different studies suggest a beneficial role of etidronate, pamidronate to a little
extent but not alendronate or ibadronate [125]. Owing to their potential effects on bone
formation and accumulation in renal failure because of their clearance by kidneys,
bisphosphonates are not recommended as a therapy for treatment of uremic vascular
calcification.
Table 2-4: Treatments directed against calcification mechanisms
Treatment

Mechanism of
Action/Outcome

References

Calcification Mechanisms
Pyrophosphates
Bisphosphonates

Thiosulfate

Reduce release of Ca2+ and
prevents hydroxyapatite
nucleation and growth

O'Neill, W.C., et al. 2010
[87]
Nitta, K., et al. 2004 [122]
Hashiba, H., et al. 2006 [123]
Ariyoshi, T., et al. 2006 [124]
Toussaint, N.D., et al. 2010
[125]

Binds with vascular calcium
salts to form a highly soluble
calcium thiosulfate salt

Araya, C.E., et al. 2006 [126]
Mataic, D., et al [127]
Adirekkiat, S., et al. 2010
[128]
Mathews, S.J., et al. 2011
[129]

Sodium thiosulfate (STS) is a small molecule acting as a vasodilator, antioxidant,
and a calcium chelator in vivo. The use of thiosulfate to treat VC was devised due to reports
that it prevents nephrolithiasis in humans, reduced tumoral calcifications in renal failure
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and significantly because it was successful in treatment of Calcific uremic arteriolopathy
(CUA) [126, 127]. In hemodialysis and peritoneal dialysis patients with CUA, parenteral
infusion of STS was able to reduce skin necrosis and calcium deposits within three months
of administration. In two preliminary studies with hemodialysis patients, STS was able to
delay the progression of CAC after 4-5 months of intravenous administration but with a
flipside of decline in bone mineral density of the hip in one study [128, 129]. Additional
clinical trials are underway, and at this time, STS is not recommended for use elsewhere.
Osteoclasts are the major mineral-resorbing cells in the body, and a landmark study
from our laboratory found that when osteoclasts were co-implanted with elastin in rats
subdermally, calcification was limited [130]. However, successful delivery and activation
of osteoclasts to the site of calcification remains a challenge.
Animal models of Vascular Calcification
Numerous animal models have been developed to study the cellular and molecular
mechanisms underlying VC, and to investigate various treatment strategies against it. A
variety of protocols in different animal species that produced calcifications at different
locations on the aorta have been documented in literature. Some well-known models
include Calcium chloride (CaCl2) injury of abdominal aorta, local intraluminal perfusion
of pancreatic elastase, systemic delivery of warfarin and vitamin K, supraphysiologic
dosages of vitamin D, nicotine used in combination with vitamin D, delivery indoxyl
sulfate, etc.
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The CaCl2 injury model has been used in rats, mice, and rabbits [131, 132]. Local
chemical damage to the abdominal aorta (or any other parts of the aortic tree such as carotid
or thoracic) by direct periadventitial application of CaCl2 causes localized medial
calcification. There is minimal injury to the arterial wall, but the acute and excessive
calcification is accompanied by elastin fiber breakdown and severe inflammation [133].
Warfarin inhibits γ-carboxylation of matrix Gla protein (MGP) and induces calcification
of the arteries similar to what is seen in an MGP-deficient mouse. Vitamin K is also used
in this model to restore normal coagulation as Warfarin is an anticoagulant, commonly
prescribed to dialysis patients [134, 135].
Calcitriol and other such vitamin D analogs are used to treat diseases in which VC
is common, such as osteoporosis and hyperparathyroidism. But toxic doses, either daily
intraperitoneal injections (1µg/kg) or supraphysiologic doses in diet (7.5 mg/kg), of
Vitamin D and its analogs, causes calcification [136-138]. This toxic effect of vitamin D
is both indirect (by causing an increase of circulating levels of Ca and P) and direct through
VSMCs. Calcitriol has been known to stimulate calcium flux into VSMCs and thus
modulates increased expression of several proteins associated with calcification.
As discussed earlier, various other stimulants have also been administered in
rodents to induce VC. Nicotine (5 ml/kg) amplifies the pro-calcific effects of vitamin D
(25 mg/kg). Vitamin D and nicotine (VDN) induces a calcium overload in the arteries,
resulting in medial and other widespread calcification [139]. The nicotine plus vitamin D
model causes calcification similar to that in a senescent man and is naturally accompanied
by systolic hypertension and LVH. Indoxyl sulfate (IS) is a uremic toxin that accelerates
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the progression of CKD. In addition, IS promotes aortic wall thickening and aortic
calcification along with colocalization of osteoblast-specific proteins. Thus, it is not only
a nephrotoxic but also acts as a vascular toxin [140].
Intraluminal infusion of elastase degrades elastin in the arteries, which in turn
localizes calcification in the abdominal aorta. This model was tested in swines and rabbits
[141]. In the elastase-treated arterial segments of swines, elastic fiber damage, reduction
of smooth muscle cells in certain areas and a significant number of necrotic lesions and
calcium deposits were observed within three weeks. New Zealand rabbit elastase-induced
aneurysm of the common carotid artery and subsequent calcification is one of the most
commonly used models to test the safety and efficacy of endovascular devices [142].
Gene deletion in mice is an extremely useful technique to unearth the precise role
of a particular protein in the development of VC. Several inhibitors, either local or
systemic, such as MGP, fetuin-A, PPi are often dysregulated during the pathophysiological
process of calcification [85, 87, 89]. Mice which are deficient in phosphaturic hormone
fibroblast growth factor (FGF) 23 and its necessary cofactor Klotho exhibit extensive
vascular and other soft tissue calcifications [85, 143]. Mice that lack MGP develop to term,
but die within a couple of months as a result of arterial calcification leading to blood vessel
rupture. MGP-deficient mice, besides, exhibit inappropriate calcification of various
cartilages, including that of the growth plate, eventually leading to short stature,
osteopenia, and fractures [84]. Osteoprotegerin (OPG) deficient mice also exhibit medial
calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling
pathway, or its ligands play a role in the association between osteoporosis and VC [144].
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Schafer et al. identified the serum protein α2-Heremans-Schmid glycoprotein (Ahsg,
commonly known as fetuin-A) as an important inhibitor of ectopic calcification acting on
a systemic level. Ahsg-deficient mice are normal phenotypically, but develop several
calcifications of various organs on a mineral and vitamin D-rich diet, and on normal diet
when the Ahsg deficiency is on a DBA/2 background [145].
Rodents have a generally high resistance to the development atherosclerotic
calcification. The lipid profile of rodents differs significantly from humans in that rodents
carry most of their plasma cholesterol in the form of high-density lipoprotein (HDL),
known to be a protector against atherosclerosis. Humans, on the other hand, have 75% of
their cholesterol on low-density lipoprotein (LDL). However, mice of C57/BL6 genetic
background are an exception.

Mice models based on interventions in lipoprotein

metabolism through genetic and dietary manipulations are most commonly used to study
atherosclerotic calcification. ApoE, a glycoprotein which is a constituent of all lipoproteins
except LDL, serves as a ligand for receptors involved in the clearance of very low-density
lipoproteins (VLDL) from circulation. Deletion of this particular ApoE gene results in a
definite increase in plasma levels of VLDL, increase in LDL to a lesser extent and a 45%
reduction in normal HDL levels leading to development of atherosclerotic lesions, mainly
in the aortic root and ascending aortas. A high fat, high cholesterol diet leads to the
development of more widely distributed and complex atherosclerotic plaques in these
ApoE knockout mice [146-148]. The LDL receptor (LDLR) knockout mice represent
another frequently used genetic model for atherosclerosis. LDLR knockout shows a modest
increase in lipid levels, doubling of plasma cholesterol mainly due to elevated LDL levels
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and little to no atherosclerosis when fed a regular chow diet. When fed with a 1.25%
cholesterol-rich diet, LDLR knockout mice display an eight-fold increase in plasma
cholesterol levels and show rapidly developing atherosclerotic lesions throughout the
length of the aorta. Administration of high-cholesterol, high-fat diet to these mice causes a
2-fold increase in aortic calcification and decreased rate of bone formation [149, 150].

Table 2-5: Animal models for in vivo calcification studies.
Type of Animal Model

Method of induction
of disease

Animal Species

References

Calcium Chloride
model

Periadventitial
application of CaCl2

Rats, Mice, Rabbits

[131-133]

Warfarin/Vitamin K

Warfarin in drinking
water/Vitamin K
Subcutaneous injections

Rats

[134, 135]

Vitamin D

Daily intraperitoneal
injections or supraphysiological vitamin D
doses in diet

Rats

[136-138]

Genetically induced
models

Knockout of regulators
of calcification (FGF23,
Klotho, MGP, OPG or
Fetuin-A)

Mice

[84, 89, 143, 144, 151,
152]

Nicotine Model; usually
used in combination
with Vitamin D

Oral administration of
Nicotine amplifies
the calcifying effects
of Vitamin D

Rat

[139]

Indoxyl Sulphate Model

Administration of
Indoxyl Sulphate in
water

Rats

[140]
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Elastase Model

Intraluminal delivery of
elastase causes
breakdown of elastin
fiber

Rats, Mice, Swine,
Rabbits

[141, 142]

5/6th Nephrectomy
Model of CKD

Reduction in renal
mass is usually installed
by a two-stage surgical
procedure:
partial nephrectomy of
one kidney and total
nephrectomy of
the contralateral kidney

Rats, Mice

[153-155]

Dietary adenine induced
CKD model

High adenine feeding
leads to structural and
functional damage to
kidneys causing
increased Serum Ca
levels and calcification

Rats, Mice

[156-159]

Genetic models of
atherosclerotic
calcification

ApoE-/- knockout mice
Ldlr-/- knockout mice

Mice

[146-150]

Animal Models of CKD with Vascular Calcification
Animal models of CKD generate a range of severity in calcification phenotype
attributable to a lack of consistency in the genetic backgrounds used, degree of kidney
damage induced, time course of study, and dietary regimen selected.
The 5/6th nephrectomy model or remnant kidney rat model reproduces experimental
CRF by mimicking the progressive loss of nephrons that occurs in human CRF. It was first
developed by Chauntin and Ferris in 1932 and has been used ever since [160]. In this
model, reduction in renal mass is usually achieved by a two-stage surgical procedure:
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partial nephrectomy of one kidney and then a total nephrectomy of the contralateral kidney.
Different methods are employed to perform the nephrectomy; resection or ligation of the
upper and lower poles of the kidney [161], cauterization or electrocoagulation of the renal
cortex and arterial ligation [162]. Out of the three, arterial ligation of 2/3rd of extrarenal
branches of the renal artery of the kidney, performed on one combined with resection of
the other kidney is the most commonly used rat model of 5/6th nephrectomy model.
However, the major limitations of 5/6th model for study of vascular calcification include
requirement of the two-step surgical procedure combined with the need to use either an
accelerating agent such as Vitamin D, excessive dietary phosphate levels or surgical
removal and replacement of parathyroid glands [163].
Rats with autosomal dominant polycystic kidney disease result in spontaneous
development of CKD over time. Heterozygous Han: SPRD rats (Cy/+) develop azotemia
at 10 weeks and progress to uremia by about 40 weeks of age, accompanied by anemia,
hypertension, hyperlipidemia, and sHPT [164, 165]. In this model, Moe et al. reported that
all three components of CKD viz., abnormal serum biochemistries, abnormal bone
remodeling and calcification of the tunica media are induced when fed a normal 0.7% P
diet. 60% of the animals developed mild to severe calcifications of the aorta after 38 weeks
of age [166]. The main disadvantage of this model, however, particularly for its usage in
interventional studies, is the very slow progression of CRF and as such the late onset of the
first calcified spots in the arteries, combined with limited reproducibility.
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Adenine-Induced Chronic Kidney Disease Model
In

normal

conditions,

adenine

is

salvaged

by

the

enzyme

adenine

phosphoribosyltransferase (APRT) enzyme and is generally present in very low levels in
circulation and urine. APRT is expressed ubiquitously in all mammalian cells and plays an
important role in the purine nucleotide salvage pathway helping in recovery of bases and
nucleosides following degradation of RNA and DNA. It represents the rate-limiting step in
the conversion of adenine and 5-phosphoribosyl-1-pyrophosphate (PRPP) to adenosine
monophosphate (AMP). ARTP catalyzes a phosphoribosyl transfer from PRPP to adenine,
forming AMP and releasing pyrophosphate.
When adenine administration exceeds a certain level, APRT activity is insufficient
and saturated. Adenine is then oxidized by xanthine dehydrogenase to 2,8
dihydroxyadenine (DHA) via an 8-hydroxyadenine intermediate product. Although DHA
is protein-bound in plasma, it has a general poor solubility in urine and gradually
precipitates in the kidney tubules, leading to the formation of kidney stones, i.e.,
nephrolithiasis [167]. If left untreated, it results in renal failure with permanent kidney
damage. The autosomal recessive metabolic disorder, APRT deficiency represents the
human counterpart of this phenomenon [168].
The adenine model has recently gained a lot of attention due to the relative ease in
design and several encouraging outcomes. Long term high adenine feeding in rats results
in certain metabolic abnormalities resembling CRF in humans. Among the disturbances
observed are azotemia, accumulation of uremic toxins, imbalance of amino acids and
electrolytes, and other hormonal imbalances [169]. Adenine forms crystals in the renal
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tubules causing subsequent tubular injury, seen as lesions in mainly proximal tubules, some
distal tubules and glomeruli, inflammation, and noticeable fibrosis. These marked kidney
damages go along with characteristic biochemical changes like significantly elevated
serum creatinine, blood urea nitrogen, and phosphorus. Renal pathology of the adenine
model resembles the clinical situation quite well with the presentation of
hyperphosphatemia, hypocalcemia, severe secondary hyperparathyroidism with high
parathyroid hormone levels, hypovitaminosis of D, and renal osteodystrophy. Okada et al.
optimized the adenine-induced CKD model in rats that closely resembles the clinical
condition in humans [170]. It has since become a useful model to study complications of
CKD in patients.
Several research groups made use of the adenine model to evaluate therapeutic
agents for prevention of medial calcification [156, 159, 171-175]. The key advantage of
the adenine model is that it does not mandate surgery to generate required levels of CKD.
However, its major drawback is that up to 50% of the animals do not show medial aortic
calcification despite the manifestation of a stable, comparable moderate-severe CKD.
Another significant disadvantage is the severe weight loss that occurs with feeding of high
adenine and ensuing mortality [176]. Price et al. introduced a variant on this model by
lowering the protein content of the adenine-rich diet to 2.5% along with high amounts of
Ca (1.06 %) and P (0.92%). This combination resulted in the development of uniformly
severe medial calcification in the aortas of all rats 4 weeks after the induction of CKD.
Lowering the protein content of the diet dramatically increases the frequency and extent of
medial artery calcification [157].
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Table 2-6: Studies with adenine-model of CKD in rodents

Animals

Diet

Duration of adenine
feeding

13 wk old SD rats

0.75% Ad
0.92% P
1.06% Ca
2.5%/25% Protein

4 wk

0.75% Ade
0.92% P
1.06% Ca

4 wk

300g SD rats

0.75%/0.5% Ad
0.92% p
10.6% Ca

4 wk

10 wk old SD rats

0.75% Ad
1.2% P
1.0% Ca

4 wk/6 wk

Neven et al. [159]

10 wk old Wistar rats

0.75% Ad
0.92% P
1.1% Ca

4 wk

Henley et al. [171]

350-390g SD rats

0.75% Ad
0.9% P
1.1% Ca

4 wk

Pasch et al. [179]

6 wk old Wistar rats

0.75% Ad
0.8% P
1.05% Ca

4 wk

Reference

Price et al. [157]

Katsumata et al.
[156]

Lomashvilli et al.
[177]

Yamada et al. [178]

12 wk old Wistar
Rats
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Chelation Therapy
Chelation has its origin in the Greek word ‘chela’ meaning claw of a lobster, thus
describing the concept of clinging or holding with a strong grip. The term chelate was first
applied by Sir Gilbert T. Morgan and H. D. K. Drew in 1920. They suggested the term for
the caliper-like groups which function as two associating units and fasten to a central atom
so as to produce heterocyclic rings [180].

Figure 2-15: Chelating agent-metal ion complex. (A) Depiction of chelating agent binding
to metal ion in a crab-like grip. (B) EDTA-Metal ligand complex [181].

Chelation therapy mainly involves the usage of Ethylene diamine tetraacetic acid
(EDTA), a chemical that binds to, or chelates ionic calcium, trace elements, and other
divalent cations. Chelation therapy can be traced back to the early 1930s when Ferdinand
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Munz, a German chemist first synthesized EDTA while he was looking for a replacement
for citric acid as a water softener [182]. Usage of chelation for therapy began during World
War II when some chemists at the University of Oxford were researching for an antidote
to lewisite, an arsenic-based chemical weapon [183]. It was learned that EDTA was
particularly effective in treating lead poisoning. Following this, chelation therapy was used
to treat workers who had painted US naval vessels with lead-based paints and were
suffering from lead poisoning. It remains in use for some very specific medical purposes,
although it needs to be administered under extremely careful supervision, owing to its
many inherent risks. In fact, it is one of the preferred medical treatments against many
forms of metal poisoning (e.g., lead, arsenic, mercury, iron, copper, and nickel) [184].
Heavy metal poisoning can be caused by drinking polluted water, breathing heavily
polluted air, and due to several conditions that lead to a buildup of toxic metals in the body,
such as Wilson’s disease, hemochromatosis, thalassemia, sickle-cell disease, etc.
Types of chelating agents
There are multitudes of chelating agents with different affinities for different
metals, physical characteristics, and their mechanism of action in the body. These agents
may be administered intravenously, intramuscularly, or orally depending on the agent and
need. Some chelating agents that have been used as chelation therapeutics for various
medical purposes against metal intoxication are listed in Table 2-7.
Apart from its usage in alternative medicine to treat metal toxicity as discussed,
chelation therapy has also been advocated for conditions like atherosclerosis, diabetes,
autism, Alzheimer’s, and Parkinson’s disease. However, all these claims are largely
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unproven, and chelation therapy is only approved by the U.S. Food and Drug
Administration (FDA) to treat metal poisoning [185, 186].
Table 2-7: Chelation therapy for metal intoxication
Type of chelating agent

Target metal and
medical application

Route of
Administration

References

EDTA

Lead, Calcium

Intravenous

[187-190]

Calcium disodium
EDTA

Mercury, Lead

Intravenous

[191-193]

STS (Sodium
thiosulfate)

Antioxidant
Cyanide Poisoning
Skin Diseases like
Acne

Intravenous

[194]
[195]

DTPA (Diethylene
triamine pentaacetic
acid)

MRI contrast agent,
Radioactive poisoning
with Plutonium,
Americum, etc.

Intravenous

[196]
[197]

Dimercaprol
also known as BAL
(British anti-Lewisite)

Arsenic, Mercury, Lead
poisoning
Copper poisoning
(Wilson’s disease)
Lewisite poisoning

DMSA
(Dimercaptosuccinic
acid)

DMPS (Dimercaptopropane sulfonate)

Mercury, Arsenic and
Lead poisoning

Acute Arsenic
poisoning
Polonium poisoning
Mercury poisoning
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[198]
Intramuscular injection

[199]
[200, 201]

Oral

[202-204]

Oral

[205]

Intravenous

[206]

D-Penicillamine

Deferoxamine and
Deferasirox

Lead, Arsenic,
Mercury poisoning
Copper poisoning in
Wilson’s disease
Iron poisoning
(Thalassaemia)
Aluminum poisoning
(Chronic renal
dialysis)

Oral or
Intravenous
injections

[207]

Intravenous injection
or
infusion

[209, 210]

[208]

EDTA Chelation Therapy
EDTA binds to and forms strong complexes with iron, mercury, lead, calcium, trace
elements, and other divalent cations. Table 2-8 shows EDTA and its binding affinity to
various metal ions.
Table 2-8: EDTA and its Log K binding constants to various metal ions.
Metal

Fe3+

Hg2+

Cu2+

Pb2+

Ni2+

Zn2+

Cd2+

Co2+

Al2+

Fe2+

Mn2+

Ca2+

Mg2+

Log K

25.1

21.8

18.8

18.5

18.0

16.5

16.5

16.3

16.1

14.3

13.7

10.7

8.7

Higher binding constants indicate the binding potential of the chelating agent to the
respective metal ion. Owing to its large binding affinity to Pb2+, EDTA has been used for
decades to treat lead poisoning, as we discussed before. EDTA also has an appreciable
binding affinity to Ca2+, therefore has been used to treat hypercalcemia, removal of calcium
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from fixed tissues and has long been advocated as an alternative treatment approach for
CVDs [9, 187, 211].
There have been many case studies and clinical trials to claim that EDTA chelation
therapy is effective against atherosclerosis, coronary heart disease, and peripheral vascular
disease. It began with Norman Clarke, Sr. and his coworkers in the 1950s who observed
that some of the workers at a battery factory had improved angina pectoris following
chelation therapy. He subsequently administered chelation therapy to patients with angina
and other occlusive vascular problems, hypothesizing that “EDTA could dissolve diseasecausing plaques in the coronary systems of humans” [188]. In a subsequent longer study,
Clarke et al. showed that 87% of patients out of 283 showed improvement in their
symptoms [212]. Quite a few investigators made similar observations about the role of
EDTA in the treatment of cardiovascular disease [213-217]. In a retrospective study of
2,870 patients treated with NaMgEDTA, Olszewer and Carter noted that EDTA chelation
therapy benefited patients with cardiac disease, peripheral vascular disease, and
cerebrovascular disease. The conclusions were unjust due to a lack of comparison with
people who did not receive the treatment. The same researchers carried out a double-blind
study in which patient progress was evaluated by measuring blood pressure changes,
performance in stress tests before, during, and after EDTA treatment. It was claimed that
the treatment showed substantial improvements in walking and master exercise tests [218].
McDonagh et al. reported a case study with 30 patients diagnosed with atherosclerotic
vascular disease and showed that EDTA chelation therapy decreased intra-arterial
obstruction and reduced stenosis [219]. In a retrospective case study in 470 patients acting
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as their own control, Claus Hancke and his group observed that 80-91% of them showed
improvement. Amongst 92 patients referred for surgical intervention, only 10 ultimately
required surgery during, or after chelation therapy [220].
Results from other randomized, placebo-controlled studies, however, do not
indicate any benefit from EDTA on CVD. The first of these studies was conducted by
Diehm et al. with 45 patients who had a high-grade arterial obstruction and intermittent
claudication, by measuring their ability to perform pain-free walking exercises along with
many other parameters. Measurements made during the 4-week treatment period, and for
3 months after treatment, showed that both EDTA and control Bencyclan groups showed
comparable improvements [221]. Guldager and coworkers published a double-blind,
placebo-controlled trial with 153 patients who received either EDTA (3g of Na2EDTA)
placebo. At the end of the 5-9 week treatment phase, there were no significant inter-group
differences in any of the outcome parameters, and the situation remained unchanged even
after 6 months of follow-up [222]. Another placebo-controlled, double-blind study was
published by van Rij et al. randomizing 32 patients with intermittent claudication into
treatment and control groups. No clinically significant differences in main outcome
measures (subjective and measured walking distances, ankle/brachial pulse indices)
between chelation therapy and placebo groups were detected up to 3 months following
treatment [223]. In 2002, Knudtson et al. enrolled 84 patients over 21 years of age with
coronary artery disease proven by angiography, or documented myocardial infarction and
stable angina. Based on exercise time to ischemia, exercise capacity, and quality of life
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measurements, they found no evidence to support a beneficial effect of chelation therapy
[224].
The use of chelation therapy to treat heart diseases and other conditions grew in the
United States by approximately 68% to about 111,000 people. The Trial to Assess
Chelation Therapy (TACT) was the first large-scale, NIH funded, multi-centered study
commissioned from 2008 to 2013 to determine the safety and efficacy of EDTA Chelation
Therapy (disodium EDTA) for individuals with a history of heart attacks. It was a study
with a large enough design to detect if there are any moderate benefits towards risks
associated with the therapy. Overall, patients who received chelation therapy had a modest
18% reduced risk of subsequent cardiac events such as heart attack, stroke, and
hospitalization for angina. These results, by themselves, are not sufficient to recommend
routine use of chelation therapy for post-heart attack situations. Interestingly, among
patients with diabetes (these patients made up 37% of the entire study population),
researchers found that those receiving chelation had a markedly lower risk of
cardiovascular events (25% in diabetic patients vs. 38% in placebo) and death due to any
cause was 43% lower [190, 225]. A new follow-up study, Trial To Assess Chelation
Therapy 2 (TACT2) commenced in December 2016 and is underway until 2021. NIH is
sponsoring TACT2 to repeat the TACT1, but only in patients with diabetes and a prior
heart attack to confirm the apparent benefit of EDTA chelation therapy in this group of
patients [226]. Despite countless claims and opinions against the use of EDTA chelation
therapy in the treatment of CVDs, there is enormous potential, as long as the possible sideeffects can be circumvented.
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Nanoparticles as drug delivery systems
In the treatment of vascular diseases, direct administration of drugs has shown
limited success largely because of rapid drug clearance, short half-life, and severe systemic
side effects. In addition, disturbed flow condition in the arteries is an important factor to
consider while developing an effective therapy for vascular disease [227]. Nanoparticles
(NPs) have certain unique features that enable them to be used in drug delivery to specific
tissues or organs to maximize the beneficial effects of the drug by improving local
availability and lower off-target complications. The tunability of their shape, size, and
surface chemistry makes NPs suitable to be programmed for site-specific delivery. NPs
achieve their central goal of site-specificity by exploring considerations of normal versus
diseased tissues to optimize their residence time [228-230].
Several types of nanocarriers have been developed for use in medicine, each with
their own advantages and disadvantages. These include micelles, reverse micelles,
dendrimers, liposomal nanocarriers, polymeric nanoparticles, nanogels, and nanocoatings.
Among these, only polymeric and liposomal nanoparticles have been extensively studied
for drug delivery in vasculature because of their high biocompatibility and
biodegradability. Further, they present a variety of possibilities for surface-modification
and high drug payload [231, 232]. Polymeric nanocarriers have proven to be more effective
in delivering drugs to vascular wall than their liposomal counterparts, owing to liposome’s
inherent issues such as thinner membranes affecting their durability, and destabilization
due to addition of polyethylene glycol (PEG). As NPs being targeted to vascular disease
have to be administered intravenously into circulation, an immune response, known as
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opsonization, to the blood proteins that are absorbed onto the particle surface will occur
[233]. This will result in the particles being quickly eliminated from circulation by the
Mononuclear phagocyte system (MPS) [234], and the desired therapeutic effect is not
achieved. Surface addition of PEG chains to polymeric NPs, a process termed PEGylation,
increases their hydrophilicity, reduces immunogenicity, and increases their retention time
by making them “stealthy”. [235].
Targeting of NPs can be achieved either by passive or active targeting mechanisms.
Passive targeting is commonly used in oncology because the tumor results in enhanced
permeability and retention (EPR) effect [236, 237]. NPs preferentially accumulate near
tumor sites due to blood vessel leakage, or limited lymphatic drainage. Active targeting is
a result of surface modifiers such as ligand/receptor, antigen/antibody, or any other form
of molecular recognition, to ensure that the NPs are guided to the tissue of interest [238,
239].
Albumin use for formulation of nanoparticles
Albumin is a versatile macromolecule for drug delivery because it is known to be
non-toxic, non-immunogenic, biocompatible, and biodegradable. In recent times, albuminbased nanoparticles have emerged as attractive drug carriers, since a significant amount of
drug can be loaded into the particle matrix because of high binding sites present in the
albumin molecule [240]. Albumin can be obtained from a variety of sources, including egg
white (ovalbumin), bovine serum albumin (BSA), and human serum albumin (HSA).
Albumin NPs are expected to be well tolerated, as evidenced by clinical studies with
registered HSA-based particles such as Albunex™[241] and Abraxane™ [242].
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Albumin nanoparticles can be prepared using a variety of techniques [240];
desolvation, emulsification, thermal gelation, nanospray drying, and nab™. In the process
of desolvation, albumin is phase-separated out from a solution by the addition of a
desolvating agent due to its diminished solubility. Glutaraldehyde is then used as a
crosslinker to harden the coacervates. Other crosslinkers, such as polyethyleneimine (PEI),
formaldehyde, and 1-ethyl-3-(3-dimethylaminopropyl) cardodiimide (EDC) have been
suggested as alternatives to glutaraldehyde for reduced toxicity [243].
Targeted or Site-specific EDTA Chelation Therapy
The usage of systemic chelation therapy with EDTA, as discussed above, requires
high dosages resulting in possible unwanted side effects such as hypocalcemia, renal
toxicity, and bone loss [10, 244]. The major drawback to any systemic treatment is that
very small amounts of the drug (in this case, chelating agent) actually reach the site of
mineralization. Another notable hurdle for systemic attempts to reverse VC is that calcium
is typically present in blood, bones, and teeth, and is required for normal functions in these
tissues. Therefore, removal of calcium from arteries through systemic approaches can have
major and potentially disastrous complications. Targeted and site-specific delivery of
EDTA could lower the dosage required and present attractive advantages such as improved
bioavailability and control over release of the chelating agent.
In our laboratory, we have developed a nanoparticle approach with albumin-based
NPs that only targets degraded elastin fiber, which is a salient feature of calcified arteries.
As noted previously, elastic fibers are made up of a core of crosslinked amorphous elastin,
and several microfibrillar glycoproteins (such as fibrillins and fibulins) on the periphery of
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the amorphous core. Consequent to elastic fiber degradation and calcification, the
surrounding microfibrillar proteins are lost, and the amorphous core is exposed. This
exposed core serves as a potential target for nanoparticles conjugated on their surface with
an elastin-specific antibody [245].

Elastin lamina degradation in diseased
artery

Figure 2-16: Elastic fiber degradation leads to exposed amorphous core

Several key studies performed and published from our laboratory have shown the
success of such site-specific targeted therapies with albumin NPs aimed to target damaged
elastic fiber in the treatment of elastin-specific diseases including abdominal aortic
aneurysm [246-248], emphysema and chronic obstructive pulmonary disease (COPD)
[249].

57

3

PROJECT RATIONALE AND SPECIFIC AIMS

Therapeutic strategies and interventions that may stabilize and potentially reverse
vascular calcification (VC) are of immense value to patients with chronic kidney disease
(CKD). As discussed at length in the previous chapter, most of the treatment methods in
use have been generally limited to optimizing and managing the dysregulated mineral
metabolism and bone turnover diseases, both of which are characteristic to CKD itself. It
is pertinent to note here that there is no consensus yet about screening for, and interventions
to retard the progression of VC. Even with the most dramatic interventions in use, namely
intense dialysis and renal replacement therapy, VC that has already manifested in patients
cannot be regressed.
Current clinical practice entirely focuses on prevention and retardation of
progression. Unfortunately, most patients remain underdiagnosed, and those diagnosed
already have heavily calcified vessels thereby remaining undertreated since preventative
strategies no longer work at this stage of diagnosis. Therefore, it becomes essential that the
process of treatment of VC involves direct interference with mineralization in the arteries
and resorption of calcified lesions. Promoting this process of reversal, while
simultaneously avoiding demineralization from tissues that normally contain calcium (i.e.,
bones and teeth) remains the most critical challenge with respect to developing a successful
treatment regimen for VC in CKD. Unfortunately, there is no FDA-approved treatment
available at this time to reverse calcification in millions of patients with CKD. Finding a
treatment approach that attacks and dissolves mineralization in the calcified arteries of
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these patients, while eluding systemic loss of calcium, thus improving arterial elasticity
remains a pressing health care necessity.
Chelating agents are chemical compounds known to react with metal ions to form
stable and water-soluble complexes. They have long been of great importance in treating
intoxications and metal overload in the body. Some critical qualities of a chelating agent
to exert its clinical effect are high affinity towards the toxic metal, forming the metalchelator complex with rapid elimination, and low toxicity. EDTA is a well-known chelator
and has a high affinity towards a variety of metal ions, including Ca2+. Ethylene glycol
tetraacetic acid (EGTA) is a polycaroboxylic acid similar to EDTA and can also act as a
chelating agent. It is reported to have a better affinity towards Ca2+ than EDTA. A
polycarboxylic acid derivate of EGTA, known as (1,2-bis(o-aminophenoxy) ethane- N, N,
N’, N’ tetraacetic acid (BAPTA), is also known for its calcium-specificity and ability to
bind two Ca2+ ions in solution, Both EGTA and BAPTA have been used to chelate Ca2+ in
buffers, especially in the presence of other metal ions like Mg2+. Because of their affinity
for Ca2+, we theorize that these chelating agents can chelate and remove Ca from
mineralized deposits.
Our innovative tactic is to target the amorphous elastin core that is exposed when
elastin fibers degrade and calcify. NPs conjugated with an anti-elastin antibody will
accumulate at the calcified sites, sparing healthy arteries and other tissues. This will allow
us to deliver any agent to these degraded and calcified elastin fibers. The chelating agent
released at these sites will dissolve and remove calcium from the mineralized deposits.
Site-specific delivery of chelating agent helps us to avoid systemic side effects commonly
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seen with intravenous chelation therapies currently in use. If successful, this approach will
create a new paradigm in the quest to invent a novel therapy for permanent reversal of
vascular calcification.
Specific Aim 1: To compare and contrast the chelating agents EGTA and BAPTA with
EDTA and deduce the chelating agent most effective in demineralizing calcium for
use in targeted chelation therapy of VC.
Rationale: EDTA is a popular chelating agent in the treatment of metal intoxication due to
lead, and calcium owing to its well-published affinity towards many metal cations. EGTA
is useful for making buffers to chelate Ca ions when they are less concentrated than others,
as found in living cells and chelating certain heavy metal poisons. BAPTA-AM has been
known to maintain intracellular Ca2+ homeostasis. In this aim, we would like to compare
the chelating ability of these three chelating agents in vitro to select the best among the
three for our targeted EDTA chelation therapy experiments.
Specific Aim 2: To investigate whether EDTA, a chelating agent, loaded nanoparticles
(NPs) can be targeted to the sites of elastin-specific medial arterial calcification
(MAC) and whether the calcification can be reversed in a renal failure model in rats.
Rationale: We have already shown elastin antibody-conjugated nanoparticle delivery
system delivers EDTA to the sites of vascular calcification in a calcium chloride abdominal
aorta injury, and calcification is eliminated from these sites. One significant limitation of
this study was that the calcification that manifests in the CaCl2 model is restricted to the
injury site in the abdominal aorta. Moreover, the calcification caused is because of an
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inflammatory response to the periadventitial application of CaCl2 and may not be relevant
clinically. Diabetic or renal failure patients would have calcification due to different
pathomechanisms, and not due to chemically created injury. To address this limitation, we
have chosen a renal failure model in rats caused by dietary administration of adenine.
Specific Aim 3: To establish and validate adenine-induced CKD model of medial
arterial calcification in mice by monitoring disease progression in vivo and exploring
VSMC status for potential use in investigating targeted EDTA chelation therapy and
effect of reversal of calcification on vascular homeostasis and function.
Rationale: As cited earlier, we and several research groups have shown VSMCs
undergoing differentiation and osteoblast-like transformation in VC. Recently, we have
shown that osteogenic transdifferentiation of VSMCs occurs when cultured on surfaces of
HA and calcified elastin. Interestingly, when cells were removed from the calcific
environment and cultured normally, they revert to their VSMC phenotype. However,
whether this is possible in vivo remains a challenge. Lineage tracing studies will be useful
to investigate the fate of VSMCs in vivo after elimination of calcification by EDTA
treatment. Since mice need to be used for lineage tracing studies, there is a need to establish
a mouse model where CKD-related MAC is manifested and can be targeted. We would
also like to develop imaging modules to track the progression of disease before and after
treatment to assess improvement in vascular health following clearance of mineralized
deposits and reverting of VSMCs to their contractile phenotype.
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Specific Aim 4: To develop an ex vivo porcine carotid artery organ culture model of
vascular calcification for evaluating whether treatment with EDTA loaded
nanoparticles conjugated with an anti-elastin antibody eliminates calcification and
reverts VSMCs to their normal phenotype
Rationale: A large number of studies have been conducted using cell cultures from mice,
bovine, and human to better understand the core mechanism of VC. High morphological
and genetic variation at higher passage numbers limit the suitability of monolayer cell
cultures to examine the influence of interaction between different cells and thus do not
provide a full picture of VC and ensuing phenomena. Organ cultures are simple, relatively
easy, and a better fit to inspect VC and nearly resemble an in vivo condition. An ex vivo
organ culture model from a larger animal than rodents would be a logical step forward. We
intend to use a porcine carotid artery organ culture model of Pi-induced calcification to
scrutinize VC and VSMC cell fate after chelation therapy.
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4

SPECIFIC AIM 1

TO COMPARE EGTA AND BAPTA WITH EDTA AND DEDUCE THE
CHELATING AGENT MOST EFFECTIVE IN DEMINERALIZING CALCIUM
FOR USE IN TARGETED CHELATION THERAPY

Introduction
EDTA is a popular chelating agent for divalent ions, which is widely used in
biochemistry, molecular biology, and cell biology. In addition to Ca, EDTA forms
especially strong complexes with Mn, Cu, Fe, Pb, and Co. Ethylene glycol-bis (βaminoethyl ether)-N, N, N´, N´-tetraacetic acid or Ethylene glycol tetraacetic acid, or
simply known as Egtazic acid is an aminopolycarboxylic acid and can act as a chelating
agent, just like EDTA. In comparison to EDTA, it has a lower affinity for Mg2+, in turn
making it more selective for Ca2+. EGTA is known for its high specificity for Ca2+, more
so in the presence of Mg2+ [250]. It has been used to buffer solutions that resemble living
cell environment, where Ca2+ ions are 1000-fold or so lesser concentrated than Mg2+ ions.
Although EDTA is in more widespread use currently, EGTA is also used in some
applications like treating animals with cerium poisoning, separation of thorium from
monazite and as a component in elution buffers for protein purification. A synthetic
derivative of EGTA, 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA),
is also known for its preference for Ca2+ ions in solution [251]. It is known to reduce
elevation of cleaved Caspase-3, block cell death by inhibiting Reacting oxygen species
(ROS) and eliminate intracellular changes of Ca2+ [252, 253].
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Here, we try to assess the Ca chelating ability of the three chelating agents with a
simple in vitro experiment using hydroxyapatite (HA) to select the better chelator for use
in targeted EDTA chelation therapy.
Materials and Methods
Demineralization of HA in vitro by chelating agents
5 mg of hydroxyapatite powder was suspended in 30 mL solutions of three different
chelating agents – EDTA, EGTA, and BAPTA. Two different concentrations (0.5 mg/mL,
5mg/mL) of each chelating agent were used. DD water was used as control group. At
regular intervals, 1mL of supernatant was withdrawn to quantify Ca that was released into
the supernatant. Samples were analyzed using the Spectro Acros ICP Spectrometer
(SPECTRO Analytical Instruments, Kleve, Germany) at Clemson University Agricultural
Service Laboratory and Ca amounts were normalized to the initial amount of HA in the
solution.
Measurement of MMP activity in tissue homogenates
MMP activity in homogenates of lung tissue samples from emphysematous mice
was measured using internally quenched peptide substrates for MMPs 2&9 (Ex/Em =
280/360 mm, MMP Substrate III, Anaspec, CA). One milligram of the substrate was
dissolved in 50µl of DMSO, and the solution was diluted in 10 ml of development buffer
(50 mM Tris Base, 5 mM CaCl2.2H20, 200 mM NaCl, 0.02% brij-35). 2 µl of the substrate
stock solution and 2 µl of the homogenized tissues were mixed with 96 µl of the
development buffer supplemented with any of the three chelating agents (EDTA, EGTA,
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BAPTA) and incubated for one hour at 37°C. A fluorescent plate reader was used to read
endpoint fluorescent intensity.
Results
Ca demineralized from HA by chelating agents
Three chelating agents (EDTA, EGTA, and BAPTA) at two different
concentrations (0.5 mg/mL and 5 mg/mL) were tested to classify the best performing
chelating agent with the highest propensity to release Ca. HA powder (5 mg in 30mL of
chelating agent solutions was extracted at different time intervals and Ca measured through
ICP analysis. EDTA was the stronger chelating agent amongst the three over a time period
of 48 hours, removing Ca from HA at higher efficiency (~63 µg of Ca/mg of HA) than
both EGTA and BAPTA, with 5 mg/mL EGTA (61.73 µg of Ca/mg of HA) reaching the
level of demineralization of EDTA. Even at a higher concentration of 50 mg/mL, BAPTA
was not as competent as EDTA in demineralizing Ca from HA powder in suspension with
Ca released into the supernatants peaking at 51.4 µg of Ca/mg of HA for 5 mg/mL
concentration. Negligible amounts of Ca were recorded with the control DD H20. The
release kinetics of all the three chelating agents are shown in Figure 4-1.

65

Figure 4-1: Demineralization and Ca release kinetics from HA by chelating agents. EDTA
releases Ca most efficiently compared to EGTA and BAPTA at both the concentrations
used.

Measurement of MMP activity in tissue homogenates
To compare the MMP inhibitory effect of the three chelating agents on the tissue
homogenates of lungs from emphysematous mice, MMP activity was measured using a
specific FRET substrate for MMP 2&9. No significant reduction of MMP activity was seen
when the development buffer was supplemented with any of the three chelating agents,
indicating that Zn2+ required for MMP activity was not chelated from solution (Figure 42).
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Figure 4-2: MMP activity by chelation of Zn2+measured using specific FRET substrates
for MMP 2&9.
Discussion
In this pilot study, we tested the efficacy for three different chelating agents known
for their affinity of Ca2+ to compare their calcium demineralization potential.
Demineralization of Ca2+ from HA shows that EGTA and BAPTA are not as effective in
dissolving Ca2+ ions as EDTA. Reduction of MMP activity by chelation of Zn2+ was not
observed with any of the three chelating agents. Although more studies are needed to
confirm better demineralization of calcium deposits with different chelating agents,

67

including testing with Magnesium-based deposits (e.g., Whitlockite), calcified elastin
fibers, and lesions. For now, EDTA was the chelator of choice.
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5

SPECIFIC AIM 2

TO INVESTIGATE WHETHER EDTA, A CHELATING AGENT, LOADED
NANOPARTICLES CAN BE TARGETED TO SITES OF ELASTIN-SPECIFIC
MEDIAL
ARTERIAL
CALCIFICATION
AND
WHETHER
THE
CALCIFICATION CAN BE REVERSED IN A RENAL FAILURE MODEL IN
RATS
Introduction
Patients with chronic kidney disease (CKD) have an elevated burden of
cardiovascular disease (CVD) and compared to age-matched individuals with normal renal
function[76, 254], are more likely to die due to CVD than to progress to renal failure.
Although a cause of such excessive cardiovascular mortality has not been singled out, a
major contributing factor is thought to be vascular calcification [76, 255].
Current therapies to treat VC, particularly in CKD, predominantly consist of
controlling the mineral disturbance and are mainly preventive in action [256, 257]. EDTA
is a promising chelating agent that can dissolve and remove calcium deposits if delivered
near the calcification[258]. We demonstrated earlier that elastin antibody-conjugated NPs
can be targeted to calcification sites and that EDTA delivered by these NPs reverses elastinspecific MAC in a rat model of CaCl2 injury[259]. However, in that study, the aortic injury
was created locally through a chemical insult, and systemic abnormalities usually
associated with diseases like renal failure were not present.
Several research groups have employed the adenine-induced model of uremia and
renal failure to characterize and investigate treatment methods for vascular calcification
[159, 177, 179]. All these studies showed a common limitation that up to 50% of the rats
fed with adenine diets do not show medial calcification in spite of a stable and comparable
69

CKD. Price et al. introduced a variant to this model by lowering the amount of protein in
the diet to 2.5% and higher amounts of P than in a standard rodent diet[157].

Renal

pathology of this model mimics the clinical situation with the development of
hyperphosphatemia, hypocalcemia, severe secondary hyperparathyroidism, and other
biochemical changes such as elevated serum creatinine and elevated blood urea nitrogen
that lead to vascular calcification. Hence, this model is considered a useful tool to study
complications of arterial calcification in CKD patients and to evaluate therapeutic agents
in the prevention of uremia-related MAC[176, 260].
In the present study, we used the adenine diet with high P and high Ca-induced
CKD rat model to test if albumin NPs loaded with EDTA delivered systemically would
target calcific sites and remove vascular mineral deposition without the side effects
associated with systemic EDTA chelation.
Materials and Methods
Preparation of BSA DiR Nanoparticles for in vivo targeting studies
DiR (1, 1-dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine iodide) (PromoCell
GmbH, Heidelberg, Germany) loaded bovine serum albumin (BSA) (Seracare, Milford,
MA) nanoparticles were prepared using desolvation method and conjugated to an antielastin antibody (US Biological, MA, USA) for targeting purposes as described [247].
Briefly, 250 mg of BSA was dissolved in 4 mL of DI water. 25 mg of DiR dye dissolved
in acetone was added to BSA solution and stirred for one hour at room temperature
following the addition of glutaraldehyde (EM grade 70%, EMS, PA, USA) at a
concentration of 42 µg/mg BSA. The mixture was added dropwise to 24 mL of ethanol
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while sonicating (Omni Ruptor 400 Ultrasonic Homogenizer, Omni International Inc,
Kennesaw, GA) on ice for 30 minutes. Nanoparticles thus obtained were separated by
centrifugation and washed. These particles were PEGylated (DSPE-PEG (2000)
Maleimide) (Avanti Polar Lipids, Inc., Alabaster, AL) and conjugated to anti-elastin
antibody following a previously described protocol [245, 246].
Preparation of EDTA-loaded nanoparticles for treatment
EDTA-loaded NPs were obtained by dissolving 200 mg of BSA (Seracare, MA)
and 100 mg of EDTA (Fisher Scientific, NJ) in 4 mL of deionized water and pH was
adjusted to 8.5 with 6N NaOH. The aqueous solution was added drop-wise to 16 mL of
ethanol under probe sonication for 1 hour. For crosslinking, glutaraldehyde at ten µg per
mg of BSA was added during sonication. The elastin antibody was conjugated in a method
similar to the DiR NPs [245].
Experimental renal failure in rats – Adenine rat model
Renal failure was induced in rats by feeding adenine diets having high P and Ca
levels. High adenine feeding resulted in crystallization of 2,8-dihydroxyadenine in renal
tubules and interstitial spaces, thereby causing nephritis, fibrosis and all metabolic
anomalies associated with chronic renal failure [176, 260]. Male Sprague-Dawley rats
(Charles River Laboratories) were fed standard diets containing 18% protein until their
body weights were close to or exceeding 300g. Animals were then fed a customized
adenine (0.75%) diet (Harlan Teklad, Madison, WI, USA) made of 2.5% protein along with
higher levels of calcium and phosphorus (1.06% and 0.92% respectively) [157]. Rats were
maintained on this diet for 28 days while their body weights and behavior were carefully
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monitored. If the weight loss was found to be more than 20% of baseline body weight,
adenine diet was replaced with rat chow for all the adenine diet-fed animals to maintain
consistency and allow them to recover their weights. Adenine diets were reintroduced once
the animals recovered their weight, and the total adenine diet feeding time was 28 days.
Control rats were fed normal chow diets without adenine for the length of the experiment.
Disease progression in live animals was monitored via high-frequency ultrasound imaging
(Vevo2100, VisualSonics, Toronto, Canada). Clemson University Animal Research
Committee approved all animal use protocols (AUP) for the experimental models. All
animals receive humane care in compliance with NIH Public Law 99-158, November 20,
1985, “Animals in Research,” revised in 2015.
Targeting and Biodistribution of NPs
After 28 days of adenine diet feeding, six rats were injected with elastin antibody
conjugated and DiR-loaded NPs via the tail vein. 24 hours later, the rats were euthanized
and organs harvested for further analysis. Serum was collected for biochemical analysis
using a standard autoanalyzer. The entire body and individual organs were imaged using a
Caliper IVIS Lumina XR (Hopkinton, MA) with Ex/Em of 745/795 nm to calculate
percentage fluorescence and targeting NPs to the site of injury in the aorta. Percentage
Fluorescence was then calculated using the equation:

fluorescence in tissue
total fluorescence in all organs
%Fluorescence = �
� *100%
𝑇𝑇ℎ𝑒𝑒 𝑑𝑑ry weight of tissue
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Treatment with EDTA nanoparticles and intravenous EDTA solution
For the treatment study, rats were fed adenine diets for 28 days and divided into
five groups randomly (n=6 per group). The first group of rats received tail vein injections
of PBS to act as a no-treatment control (Saline-IV). The second group of rats received tail
vein injections of blank BSA NPs without EDTA but conjugated with anti-elastin antibody
suspended in PBS as controls (Blank-NPs). The third group of rats was given intravenous
injections of EDTA solution (EDTA-IV) in PBS twice a week for two weeks at a dosage
of 3mg/kg body weight. The fourth group received tail vein injections of NPs loaded with
EDTA and conjugated with anti-elastin antibody suspended in PBS twice a week for two
weeks (EDTA-NPs). The last group received EDTA-NPs and was allowed to survive for
four weeks after treatment (EDTA-NPs-LT). Animals were euthanized by exsanguination
while under isoflurane, aortas (from the arch to the iliac bifurcation) were collected as a
unit and fixed in 10% neutral buffered formalin. Other organs including kidneys, hearts,
liver, spleen, and lungs were also harvested. Serum was collected from animals of all the
groups for biochemical analysis. The complete schematic of the present study is elucidated
in Figure 4-1.
Whole-mount aorta alizarin red S staining
The whole aortic tree from ascending aorta to iliac bifurcation was carefully
cleaned of adherent tissues and soaked in freshly made 2% alizarin red solution (pH 4.14.3) for 10 minutes and washed with DI water for ten more minutes. The aortas were then
imaged by the stereomicroscope (Leica M125 stereo microscope, Leica Microsystems Inc.
Buffalo Grove, IL).
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Figure 5-1: Schematic representation of Specific Aim 1 study design.

Histology of aorta and kidneys
Aortas and kidneys were fixed in buffered formalin, embedded in paraffin and
sectioned per standard procedures. Five-micrometer sections were mounted on positively
charged glass slides. Slides were baked overnight at 56°C in an oven to adhere tissues to
the slides and melt the paraffin. Subsequently, the slides were deparaffinized with xylenes
followed by dehydration with graded ethanol. Aorta slides were stained with hematoxylin
and eosin for overall tissue morphology, Verhoeff-van Gieson (VVG) for elastin fibers and
Von Kossa stain with neutral fast red counterstain for calcium deposits. Kidney slides were
stained with hematoxylin and eosin for morphology, Periodic acid-Schiff stain (PAS) for
polysaccharides and mucosubstances, and with trichrome for muscle and collagen.
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Immunohistochemical analysis of the aorta
Aortas fixed in formalin were embedded in paraffin and sectioned as described
earlier. Subsequently, xylenes and graded ethanol were used to deparaffinize the sections,
and heat-induced antigen epitope retrieval was performed using citrate buffer (Thermo
Scientific, MA). The slides were then incubated overnight at 4°C with primary antibodies
— Mouse anti-Rat Alpha Smooth Muscle Actin (Biolegend, San Diego, CA), Rabbit antiRat Caspase-3 (Cell Signaling Technology, Danvers, MA), Rabbit anti-Rat MMP-2 and
Rabbit anti-Rat MMP-9 (Enzo Life Sciences, NY). Staining with relevant secondary
antibodies was completed using IHC kit (Enzo Life Sciences, NY). Slides were visualized
by either 3,3´-Diaminobenzidine (DAB) or 3-Amino-9-ethylcarbazole (AEC) chromogens
followed by an appropriate counterstain.
Quantification of aortic calcium
Calcium content in the aortas was measured after lyophilizing the part of the tissue
at renal bifurcation that showed some alizarin red S stain in the whole mount. The
lyophilized tissue was hydrolyzed in 6N HCl at 95°C and dried under a continuous stream
of nitrogen for about 45 minutes. The residue was subsequently reconstituted in 0.01N
HCl, and samples were analyzed using the Spectro Acros ICP Spectrometer (SPECTRO
Analytical Instruments, Kleve, Germany) at Clemson University Agricultural Service
Laboratory.
Ultrasound analysis of the aorta
A high-frequency ultrasound machine (Vevo2100, VisualSonics, Toronto, Canada)
was used to image and monitor the aortas of the rats at different time intervals by utilizing

75

a linear array probe (MS 400D, frequency 18-38MHz). While being imaged, the animals
were given light anesthesia by inhalation of 2% isoflurane and were placed in the supine
position on the imaging table. Aortic stiffness parameters circumferential strain and pulse
wave velocity (PWV) were calculated from the M-Mode and EKV images obtained with
the scans, respectively.
Circumferential Green-LaGrange strain was calculated with the assumption that the
strain is uniform around the vessel using the equation given below

1
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 2
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = ��
� − 1� ∗ 100
2 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
Bone integrity as evaluated by micro CT scanning
Femoral bones harvested from the rats were wrapped with parafilm to prevent
drying and scanned using a high performance in vivo micro CT scanner (Skyscan 1176,
Bruker BioSpin, Billerica, MA). Reconstruction was carried out employing a Feldkamp
algorithm using the built-in Skyscan Nrecon software. Functional mechanical testing of
bone was performed on the rat femurs using a Bose test instrument (Electroforce 3200,
Bose, MN, USA) and exposing them to escalating forces until fracture. At fracture,
maximum load (N) was determined.
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Statistics
All the results, including graphs in the figures, are given as mean±S.D. Statistical
analysis was performed using a one-way analysis of variance (ANOVA). Results were
considered to be significant when p-values ≤0.05. Tukey’s HSD was then used post-hoc to
identify the treatment groups with a significant difference.

Results
Nanoparticle preparation and characterization
EDTA-loaded NPs were prepared based on the procedure described previously our
laboratory. They were then characterized by TEM and particle size analyzer for size and
surface zeta potential. NPs had a final average size of 254.42±31.8nm; Zeta potential of
the NPs was measured as -24.42±4.49mv. The average yield of NPs after centrifugation
was 53.18±1.50%. EDTA loading into the NPs was 25.88±0.172% (Figure 5-2 A). EDTA
was released from these particles over a period of 72 hours (Figure 5-2 B).
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Figure 5-2: EDTA NPs characterization and release kinetics. (A) TEM Imaging for NP
particle size. Table below the TEM shows average particle size, surface zeta potential,
average final yield of NPs and drug loading percentage. (B) In vitro EDTA release from
NPs.
Adenine-induced renal failure model
Rats were fed adenine diets containing higher phosphate and calcium for 28 days
to induce renal failure and vascular calcification. Body weights measured during the
experiment indicated that the adenine diet-fed rats lost weight, possibly due to malnutrition
and starvation (Figure 5-3). Modulating the adenine diet feeding, as explained in the
methods section, enabled us to eliminate possible mortality in this model. All the animals
survived until the end of the study, at which time they were electively euthanized.
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Figure 5-3: Body weights of rats monitored during adenine-diet feeding.
Morphology of kidneys and serum biochemistry
Harvested kidneys from the adenine-fed rats showed extensive morphological
damage with crystal deposition in comparison to a standard diet-fed kidney (Figure 5-4 A).
Histology of kidneys from adenine-fed rats revealed increased infiltration of inflammatory
cells and fibrosis. Structural changes were severe and predominant in these rats validated
by increased vacuolation of tubules, tubular atrophy, and an increased number of tubules
with cell debris (Figure 5-4 B). Induction of CKD was further evidenced by higher serum
creatinine and blood urea nitrogen (BUN) concentrations in the adenine-fed rats compared
to normal animals. Furthermore, these animals also exhibited high serum phosphate and
uric acid concentrations (Table 5-1).
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Figure 5-4: Morphology and histology of rat kidneys. (A) Gross morphological images of
normal diet- and adenine diet-fed kidneys. (B) Histological staining of kidneys in normaland adenine diet-fed kidneys – H&E (b1-b2), Periodic acid-Schiff (b3-b4), and Masson’s
trichrome (b5-b6).
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Table 5-1: Serum biochemistry of adenine-fed rats (n=6 per group)
Normal diet

Adenine diet

Serum Creatinine
(mg/dL)

0.25±0.11

2.79±1.30*

Serum Phosphate
(mg/dL)

7.58±0.25

11.42±4.34*

Serum Calcium
(mg/dL)

10.00±0.29

10.27±0.42

BUN (mg/dL)

15.50±1.50

53.34±10.09*

Uric Acid (mmol/L)

0.73±0.12

1.44±0.15*

>60
15.34±4.11
GFR
* represents statistical significance (Student’s unpaired t-test, p < 0.05)
Organ distribution of NPs and targeting to damaged aorta
Elastin antibody conjugated and DiR dye loaded NPs were injected through the tail
vein of the rats after 28 days of feeding adenine. The NPs targeted the calcified and
degraded aortic elastic lamina sites within 24 hours while sparing the healthy regions of
the aorta in 4 out of 6 rats injected with DiR-NPs, which correlated with elastin damage.
Animals that were fed normal diets did not show any targeting of the NPs to the aorta
(Figure 5-5 A). The percentage fluorescence intensity normalized to the tissue weight for
various organs showed 69.16±14.27% targeting of NPs to the calcification sites (Figure 55 B). Representative histological sections of the aortas showed that there was indeed
degraded elastic lamina in the medial layers of the aorta as shown by VVG staining (Figure
5-6 a1-b1) and calcification of the damaged/degraded elastic lamina as shown by von
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Kossa staining (Figure 5-6 a2-b2). NPs loaded with DiR dye were infiltrating the
calcification site through adventitia in the adenine fed rats and reached the medial
calcification sites (Figure 5-6 a3-b3).

Figure 5-5: Nanoparticle targeting to diseased rat aortas (n=6). (A) NP accumulation in
aorta following systemic IV injection of EL-DIR-NPs. (B) Organ distribution of NPs as
measured by fluorescence intensity on iVIS imaging system.

Figure 5-6: Histology of the aortas in adenine diet- and control diet- fed rats (n=6 per
group).
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Targeted EDTA Chelation Therapy leads to reversal of calcification
Quantitative calcium content of the aortic tissues showed the highest calcium
content (13.47±3.5 µg/mg of the aorta) in intravenous saline (Saline-IV) group. There was
a slight decrease in systemic intravenous EDTA (EDTA-IV) group (9.82±3.3% µg/mg),
but the decrease was not statistically significant. EDTA-loaded targeted NPs (EDTA-NPs)
group showed the least calcium content (6.4±3.2% µg/mg). This was significantly different
from the Saline-IV group, which was further reduced in EDTA-NPs-LT group suggesting
that removal of calcification continued even after NP therapy was halted (Figure 5-7).
Aortic calcification evaluated by stereomicroscopic images of alizarin red-stained whole
aortas corroborated the quantitative calcium results. Rats treated with EDTA-NPs and
EDTA-NPs-LT showed significant elimination of the calcific spots, suggesting a reversal
of mineral deposition (Figure 5-8 A: a4, a5). Representative histology of the aortas stained
with von Kossa stain showed pronounced calcification of the medial layer in the Saline-IV
and Blank-NP groups (Figure 5-8 B: b1, b2). This was to some extent reduced in aortas
treated with EDTA-IV (Figure 5-8 B: b3), but it was completely absent in EDTA NPs and
EDTA-NPs-LT groups, clearly suggesting that EDTA-removed calcium deposits and
calcification did not return even after EDTA treatment was stopped for four weeks (Figure
5-8 B: b4, b5).
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Figure 5-7: Quantification of calcium in the aorta of all the treatment groups. (n=6). (*,
p<0.05, One –way ANOVA with Tukey’s HSD). Solid line represents mean value.

Figure 5-8: Histological staining of aorta for calcification in all the treatment groups. (A)
Whole mount aortas stained with alizarin red S to visualize calcium. (B) Cross-sections of
aortas stained with von Kossa stain for Ca deposits.
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Serum biochemistry following EDTA nanoparticle treatment
Serum biochemistry measurements following chelation therapy show reduced
creatinine and P levels in all the groups, including the Saline-IV and Blank-NP groups.
This may be due to the adenine diet being discontinued during therapy. BUN, Uric Acid,
however, remained high in all the groups. No morphological of histopathological
differences were seen in kidneys from all the treatment groups compared to kidneys from
adenine-fed rats before the treatment (Table 4-2).

Table 4-2: Serum biochemistry following chelation therapy. (n=6 per group).
Saline-IV

Blank-NPs

EDTA-IV

EDTA-NPs

EDTANPs-LT

Serum
Creatinine

0.53±0.10

0.70±0.23

0.63±1.1

0.73±0.26

0.46±0.00

Serum
Phosphate

8.46±0.54

8.66±0.46

8.62±0.48

7.95±0.88

8.10±0.50

Serum
Calcium

10.167±0.24

10.333±0.359

10.15±0.3

10.30±0.30

10.36±0.23

BUN

30.167±3.1

31.66±7.63

36.50±5.85

46.16±14.53

25.80±5.11

Uric Acid

1.62±0.18

1.58±0.34

1.42±0.21

1.317±0.2

1.26±0.1
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Immunohistochemical analyses of the aorta for SMC phenotype and
MMPs
Staining for alpha-smooth muscle actin indicated the loss of SMCs in the SalineIV group due to calcification compared to a normal diet-fed control rat (Figure 5-9 A: a1,
a2). SMC staining increased significantly in the EDTA-NPs and EDTA-NPs-LT groups,
indicating that the removal calcification allowed restoration of SMC phenotype in the
medial layer (Figure 5-9 A: a3, a4). To explore if the loss of VSMCs was because of
apoptosis, Caspase-3 staining with 3,3´-Diaminobenzidine chromogen was performed.
Caspase-3 marker was not detectable in a normal diet-fed rat, and it increased around the
calcific sites in Saline-IV group (Figure 5-9 B: b1, b2). Apoptotic activity was considerably
reduced in EDTA NPs and EDTA-NPs-LT groups, clearly suggesting that apoptotic cells
were replaced by healthy cells (Figure 5-9 B: b3, b4).

Figure 5-9: Immunohistochemical staining of the aortas for VSMC status in the treatment
groups. (A) Representative images of IHC staining for anti-alpha smooth muscle actin. (B)
IHC staining for caspase-3 showing apoptotic activity. (Insets in each image show
respective secondary antibody controls).
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Anti MMP-2 staining showed that MMP-2 activity was present in the calcified
regions of the aorta in Saline-IV with no detectable MMP activity in a normal diet-fed rat
(Figure 5-10 A: a1, a2). Treatment with EDTA-NPs slightly reduced MMP-2 activity,
while EDTA-NPs-LT group showed the absence of MMP-2 staining in the medial layers
(Figure 5-10 A: a3, a4). Staining for MMP-9 also was present in the calcified regions of
the medial layers of the adenine diet-fed rat aortas in Saline-IV and absent in a normal rat
aorta (Figure 5-10 B: b1, b2). MMP-9 activity was significantly reduced in both the EDTA
NP treatment groups –EDTA-NPs and EDTA-NPs-LT (Figure 5-10 B: b1, b2).

Figure 5-10: Immunohistochemical staining of the aortas for matrix metalloproteinases
(MMPs) in the treatment groups. (A) Representative images of IHC staining for MMP-2.
(B) IHC staining for MMP-9. (Insets in each image show respective secondary antibody
controls).
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In vivo ultrasound imaging
Ultrasound images of abdominal aortas were obtained during adenine diet feeding
and after therapy. Healthy aortas from standard chow-fed rats showed thin and elastic
aortas. In rats fed with the adenine diet, substantial calcification was seen in the medial
layer of the abdominal aorta (Figure 5-11 A: a1, a2). Among the treatment groups,
calcification was observed to be noticeably reduced only in the EDTA-NPs group; the
Saline-IV, Blank-NPs and EDTA-IV groups all showed the persistence of calcification
(Figure 5-11 A: a3 – a6). Circumferential strains of the healthy aortas, as calculated from
the Green-LaGrange strain equation, were 11.99±1.043% (n=6). Strains in the rats fed with
adenine diet for 28 days showed decreased circumferential strains, suggesting stiffening of
the artery due to aortic mineralization. Saline-IV, Blank-NPs, and EDTA-IV groups did
not reduce calcification; thus, aortic stiffness remained unimproved. Only EDTA-NPs
group showed a statistically significant improvement in circumferential strain
(9.22±1.05%) compared to the rest of the groups, suggesting that removal of the mineral
content led to more elastic aortas (Figure 5-11 B).
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Figure 5-11: In vivo ultrasound imaging of the rat aortas. (A) Representative 2D B-mode
images from control and all treatment groups. (B) Circumferential strain, as calculated
from Green-LaGrange equation using M-Mode images. (n=6). (*, p<0.05, One –way
ANOVA with Tukey’s HSD). Solid line represents mean value
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Bone morphology and functional testing
Representative 2D-image from micro CT scans of the femurs about 10 mm below
the trochanter revealed reduced mineralization in all the groups. EDTA-NPs group did not
show any additional reduction in mineralization compared to any other group fed with
adenine diet, indicating that EDTA NPs did not cause structural damage to the bone (Figure
5-12 a). Functional studies on bone stability indicated that the maximum load needed to
fracture the femurs did not differ significantly among the four treatment groups. This
confirmed that bone stability was not affected by EDTA-NPs treatment (Figure 5-12 b).

Figure 5-12: Morphology and functional testing of rat femurs from all the treatment
groups. (a) Representative two-dimensional slices from microcomputed tomography of rat
femurs from the different treatment groups. (b) Maximum load before breaking for femoral
bone in the treatment groups.
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Discussion
In this aim, our goal was to test whether elastin-specific MAC could be reversed by
targeted EDTA chelation therapy in a clinically relevant model of CKD.

To our

knowledge, we, for the first time demonstrated that targeted nanoparticles injected
systemically could target the calcified arteries and remove calcification in a CKD model in
rats despite altered blood biochemistry.
Over the last few years, several research groups have made use of the
adenine model for studying mechanisms of MAC in CKD [157, 175, 178, 260-262]. We
were able to successfully induce CKD in rats fed with 0.75% adenine supplemented by
high concentrations of Ca and P. Along with the expected structural damage to kidneys,
biochemical abnormalities like elevated serum creatinine, serum phosphate, and higher
levels of the BUN were seen. This closely resembled CRF in humans, making the model
useful for the study of our targeted chelation therapy.
Several research groups have reported that one of the chief limitations of the
adenine model is that a small dose of adenine (0.2%) causes inconsistent calcification, and
a high dose (0.75%) causes excessive mortality [176, 260]. In our studies, carefully
controlled 0.75% adenine-feeding led to medial vascular calcification without undue
mortality. Albumin NPs conjugated with elastin-antibody, which recognizes only damaged
elastin in the vasculature, were used to deliver EDTA to the calcification sites in animals
fed adenine diets. Fluorescence intensity of DiR dye-loaded animals showed accumulation
of NPs at calcification sites. The healthy regions of the aorta in these animals and the entire
aorta in the rats fed rat chow diets were spared, demonstrating that NPs targeted only
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degraded elastin. In previous studies, we showed that nanoparticles conjugated with
generic IgG antibody do not target damaged elastin site [245, 246, 248, 259], suggesting
that our elastin antibody conjugation led to site specificity. NPs also accumulated in liver
and spleen, possibly because they are taken up by Kupffer cells in the liver and due to
reticuloendothelial clearance [263]. This is very common for many nanoparticle therapies
[264, 265]. Moreover, we observed that the NPs entered the media from the adventitial side
through the vasa vasorum [245, 246]. Such adventitial delivery is advantageous: Often,
intraluminal thrombus or atherosclerosis can hinder particles targeted from the lumen side.
Having established targeting efficiency of NPs to the calcified sites, we proceed to
test reversal of calcification by delivering EDTA-loaded NPs. We prepared albumin
nanoparticles loaded with EDTA following an established procedure [259]. Previously, we
showed that such nanoparticles release EDTA slowly over a period of 72 hours. Our
previous studies also showed, both in vitro and in vivo, that when EDTA was delivered in
proximity to calcific deposits, EDTA removed the calcification [258, 259]. In this study,
we chose to inject NPs twice a week for two weeks based on the release profile for EDTA.
We included systemic EDTA injections as controls, at a dosage similar to the chelating
agent released from our nanoparticles. After the two weeks of injections, we observed that
the EDTA-loaded NPs reversed calcium deposits in the rat arteries, as confirmed by in vivo
ultrasound, whole-mount aorta alizarin red stain, histology with von Kossa stain, and
quantitative calcium levels. When EDTA alone was injected systemically, calcification
was reversed only slightly; therefore, multiple injections or a higher concentration of
EDTA will be required to achieve reversal. That can lead to systemic side effects as shown
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previously with systemic EDTA therapy[179, 266, 267]. As expected, when the rats were
injected with saline only and blank NPs as controls, the calcium deposits were not removed,
and aortas remained calcified and stiff. We checked the status of kidneys in all animals at
the end of the therapy by measuring blood biochemistry (Table 4-2). As the adenine diet
was not continued during the two-week therapy, we did find reduced creatinine and P levels
in all groups (including Saline-IV and Blank-NP groups) while BUN, uric acid remained
high. This showed that EDTA therapy did not affect kidney function. Stopping the adenine
diet might have improved kidney function in all groups, but once vascular calcification
developed, it did not regress as can be seen in saline and Blank-NP groups. We saw a
significant reduction in vascular calcification only after targeted therapy.
Elevated MMPs have been reported to have a strong correlation with elastic fiber
degradation, stiffness, and calcification. Particularly, MMP-2 and MMP-9 up-regulation
have been associated with arterial stiffening in diabetic patients with CKD [268].
Immunohistochemical staining for MMP-2 and MMP-9 showed that both were indeed
present in the calcified regions of the aorta in adenine-fed rats. This suggests that MMP-2
and MMP-9 may be involved in elastin degradation and eventually causing elastin
calcification in the adenine model. We showed that MMP-9 and MMP-9 knockout mice
did not show vascular calcification in a CaCl2 injury model [131]. Significant reduction in
both MMP-2 and MMP-9 after removal of calcification suggests that the inflammatory
cascade is reversed after removal of calcification. It may be that locally delivered EDTA
chelated Zn2+ ions required for MMP activity and inhibited MMPs as shown earlier by
others[269, 270], but this needs to be studied in detail.
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We also evaluated cellular status in the aorta after adenine diet-induced
calcification and after the therapy. Others showed that after adenine diet, SMCs lost
phenotype and underwent apoptosis, and those apoptotic bodies aggravated calcification
[94, 271]. In the in vivo studies described here, we saw the loss of SMC phenotype and
increased apoptosis in cells close to medial calcification. Surprisingly, we found that after
removal of calcification, there was an increase in SMC-type staining in the medial layers
of the aorta. Further cell tracing studies are necessary to investigate if the higher SMCs
seen after -treatment we due to dedifferentiation or repopulation by recruitment of HSCs,
pericytes, or by EMT.
High-frequency ultrasound imaging helped us study changes to the aorta in vivo. It
was shown that a reduced circumferential strain is an indicator of aortic stiffness[272].
Circumferential strains measured from M-mode images in healthy aortas were as reported
in the literature. We observed that circumferential strain is reduced after adenine-diet
feeding; this indicated increased aortic stiffness caused by calcification. EDTA NPs
treatment removed calcium deposits and improved the circumferential strain levels, aortic
elasticity, and health.
One important observation was that MMP activity and calcification did not return
even after EDTA therapy was suspended for four weeks (EDTA-NP-LT group) although
that CKD was present in the animals. EDTA targeted therapy did not cause any undue side
effects in bone and mineral metabolism and biomechanics. Micro CT scanning to study
bone morphology showed reduced mineralization in all groups. This was expected, as
uremia is associated with reduced bone mineral density [179]. EDTA NPs group showed

94

no additional reduction in mineral density when compared to the Saline-IV and the BlankNPs group. We showed earlier that polyphenols such as PGG, when delivered with
nanoparticles, do regenerate degraded aortic elastin [247]. Thus, there is an exciting
opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and
then restore medial elastin layers with PGG.
In conclusion, we demonstrated that targeted delivery of minimal doses of EDTA
is an effective way to reverse calcification in an experimental rat model of CKD. This
establishes the enormous potential for targeted EDTA chelation therapy as a viable clinical
alternative to reverse vascular calcification in CKD patients.
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6

SPECIFIC AIM 3

TO ESTABLISH AND VALIDATE ADENINE-INDUCED CKD MODEL OF
MEDIAL ARTERIAL CALCIFICATION IN MICE BY MONITORING DISEASE
PROGRESSION IN VIVO AND EXPLORING VSMC STATUS FOR POTENTIAL
USE IN INVESTIGATING TARGETED EDTA CHELATION THERAPY AND
EFFECT OF REVERSAL OF CALCIFICATION ON VASCULAR
HOMEOSTASIS AND FUNCTION.
Introduction
In our studies with adenine model in rats, the animals were placed back on the
standard diet during the course of chelation therapy after renal failure was established and
calcified manifested. We do not know at this point if persistence of high circulating levels
of Ca and P due to continuing adenine diet will result in return of calcification. There is a
likelihood that the degraded elastin and calcium-binding sites will remain open after
chelation and calcification may return in due course.
Moreover, our laboratory and several other research groups have shown that
VSMCs begin to undergo osteogenic differentiation with transformation into osteoblastlike cells during the process of calcification [273, 274]. VSMC phenotypic alteration is
accompanied by increased expression of proteins associated with bone such as Osteocalcin
(OCN), Osteopontin (OPN), Runt-related transcription factor (RUNX-2), Bone
morphogenic protein-2 (BMP-2) and increased Alkaline phosphatase (ALP) activity [79,
275, 276]. Increased levels of Ca and P levels, as seen in CKD patients, may accelerate
mineral deposition and result in early calcification around elastin fibers [275]. More
recently, we have shown that osteogenic transdifferentiation of VSMCs occurs when
cultured on surfaces of HA and calcified elastin [273]. Remarkably, when cells were
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removed from the calcific environment and returned to normal culture, they revert to their
VSMC phenotype [274]. However, the feasibility of this phenotypic reversal of VSMCs,
once the calcification is removed, in vivo remains unseen and open to investigation.
It would be intriguing to explore whether reversal of calcification through targeted
EDTA chelation therapy can revert this expected phenotypic transformation of VSMCs in
vivo. Our imminent goal is to investigate this phenomenon in an animal model of MAC
caused by CKD. To test this hypothesis, extensive cell lineage tracing studies are needed
to examine smooth muscle cell fate during calcification and after therapy. Mice present the
possibility of genetic manipulation, thus offering avenues to inspect cellular and molecular
mechanisms of disease progression and therapeutic effects in detail.
In the current aim, we sought to establish and validate the adenine-induced CKD
model of MAC in mice in our laboratory for monitoring the progression of calcification in
vivo and to explore VSMC status in calcified aortas. Our primary objective was to target
our nanoparticle delivery system to diseased regions of calcified aortas in mice for potential
delivery of chelating agent EDTA and therapeutics. We further studied global gene
expression profiles of VSMCs to ascertain transdifferentiation into osteogenic phenotype.
This model will provide a basis for investigating if targeted EDTA chelation therapy can
restore VSMC cellular status and reinstate vascular homeostasis.
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Materials and methods
Adenine-induced renal failure in mice
Six- to eight-week old mice with C57BL/6J genetic background (Jackson
Laboratories) were housed in standard cages with wood chip bedding and paper roll for
enrichment at ambient temperature (21-22°C) in a 12-hour light cycle. Mice were allowed
to acclimatize to the conditions of the animal facility for a period of 7 days before the start
of the experiment. For adenine-rich feeding, customized diets were purchased (Envigo
Teklad, Madison, WI, USA). A 0.2% adenine diet was formulated to have similarities to
the ones described in literature with 20% casein to make the diet more palatable for the
mice, containing 0.9% P and 0.6% Ca. A high phosphate containing diet was also
formulated with 20% casein, 0.6% Ca but with a 1.8% concentration of P. The mice were
fed with the 0.2% adenine diet for a period of 4 weeks to induce CKD followed by 0.2%
and high P diet for a further 4 weeks to produce arterial calcification (Ade+hP). The second
group of mice was fed the 0.2% adenine and 0.9% P diet throughout the length of the study
(Ade+nP). Animals were monitored regularly for expected loss of body weight and diets
were intermittently switched to standard chow diet to allow weight recovery, resulting in
zero unexpected mortality. Control group mice were fed standard chow diet throughout.
In vivo micro CT scan
A desktop in vivo X-ray micro-CT system (Skyscan 1172, Bruker Biospin) was
used to obtain micro-CT images. With this system, both the X-ray source and the detector
rotate around the animal. The mice were anesthetized with inhalation of isoflurane. A 0.2µ
aluminum filter and a 90 kV tube voltage with an exposure time of 200ms were chosen as
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the in vivo scanning parameters. Animals were placed on their back in the bed of scanner,
and images were obtained at 18µm resolution with a rotational step of 0.7°. These settings
allowed us to scan the axial length of the thorax in ~20 times of total exposure time.
Transverse, Coronal, and Sagital virtual cross-sections were reconstructed by Feldkamp
cone-beam algorithm using the in-built NRecon software. Finally, 3D models of
reconstructed aortic scans were created by segmenting them out from other bodily tissues
and fluids using a set of operations provided on the CTAn software.
Ultrasound imaging of aortas in vivo
Mice were scanned with a high-frequency ultrasound machine (Vevo2100,
VisualSonics, Toronto, Canada) to image and monitor their aortas at regular time points
during the study by utilizing a linear array probe (MS550D, frequency 22-55 MHz).
Animals were placed in the supine position on the imaging table and anesthetized during
scanning through inhalation of 2% isoflurane. Aortic stiffness parameters circumferential
strain and pulse wave velocity (PWV) were calculated from the M-Mode and PW (Pulsedwave) Doppler mode images obtained with the scans, respectively.
Measurement of aortic circumferential strain
Circumferential Green-LaGrange strain was calculated with the assumption that the
strain is uniform around the vessel using the equation given below

1
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 2
� − 1� ∗ 100
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = ��
2 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
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Measurement of local pulse wave velocity (PWV)
Local PWV measurement made on a short segment of an artery can work as an
early diagnostic tool to identify local stiffness of the arterial wall. PWV velocity at several
short segments of the aorta was calculated indirectly using the parameters obtained from
Color Doppler and PW Doppler mode images using the formula:

𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 (𝑃𝑃𝑃𝑃𝑃𝑃) =

𝐷𝐷
∆𝑇𝑇

where 𝐷𝐷 is the distance between two points along the aorta traveled by the pulse

wave and ∆𝑇𝑇 is the transit time or time delay between the two points. Time from the R

wave on the ECG to the ‘foot’ of the Doppler waveform is calculated for the two points
and the difference is recorded as transit time.
Targeting and Biodistribution of NPs
At the end of customized diet feeding in all the three groups, mice were injected
with DiR-loaded and elastin antibody conjugated (ELN-DiR-NPs) via the tail vein. 24
hours later, the mice were euthanized, and organs harvested for further analysis. Serum
was collected for biochemical analysis using a standard autoanalyzer. The entire body and
individual organs were imaged using a Caliper IVIS Lumina XR (Hopkinton, MA) with
Ex/Em of 745/795 nm to calculate percentage fluorescence and targeting NPs to the site of
injury in the aorta. Percentage Fluorescence was then calculated using the equation:
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fluorescence in tissue
total fluorescence in all organs
%Fluorescence = �
� *100%
𝑇𝑇ℎ𝑒𝑒 𝑑𝑑ry weight of tissue
The overall design of the study is illustrated in Figure 6-1.

Figure 6-1: Schematic diagram of the adenine mice study. (n=6 per group per experiment).

Alizarin red staining of the whole mount aortas
Briefly, whole aortas were carefully cleaned of adherent tissues and soaked in
freshly made 2% alizarin red solution (pH 4.1-4.3) for 10 minutes and washed with DI
water for 10 more minutes. The aortas were then imaged by the stereomicroscope (Leica
M125 stereo microscope, Leica Microsystems Inc. Buffalo Grove, IL). This will indicate
regions of possible calcification on the aorta which are further analyzed as described next.
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Histology of kidneys
Kidneys were fixed in buffered formalin, embedded in paraffin and sectioned
according to standard procedures. They were then stained with Hematoxylin and Eosin for
overall morphology, Periodic acid-Schiff stain (PAS) for polysaccharides and
mucosubstances, Trichrome for muscle and collagen.
Histology of aorta cross-sections
Segments of aortas from regions where DiR fluorescence was seen on the iVIS
system were embedded Tissue Tek OCT compound, and 5 µm sections were mounted on
charged slides by cryosectioning. Slides were fixed in cold acetone, air-dried at room
temperature and then used for staining. The following histological stains were used:
Hematoxylin and eosin (H&E) for overall tissue morphology, Alizarin Red with Light
Green SF yellowish counterstain to detect calcification, von Kossa stain with neutral fast
red counterstain for calcium deposits and Verhoeff-van Gieson (VVG) stain for elastin
fibers.
Quantification of aortic calcium
Calcium content in the aortas was measured after lyophilizing a section of the whole
aorta. The lyophilized tissue was hydrolyzed in 6N HCl at 95°C and dried under a
continuous stream of nitrogen for about 45 minutes. The residue was subsequently
reconstituted in 0.01N HCl, and samples were analyzed using the Spectro Acros ICP
Spectrometer (SPECTRO Analytical Instruments, Kleve, Germany) at Clemson University
Agricultural Service Laboratory.
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Immunohistochemistry for VSMC status
Briefly, OCT compound was washed off the tissue sections (5 μm), and they were
placed in a water bath containing citrate buffer (10 mM Sodium Citrate, 0.05% Tween 20,
pH 6.0) inside a pressure cooker to achieve heat-induced unmasking of antigens.
Endogenous peroxidases were quenched with 3% hydrogen peroxide. Non-specific
background was eliminated by treating the sections with Background Buster (Innovex) for
1hr at RT. Primary Antibodies against were applied overnight at 4°C against Alpha smooth
muscle actin (ACTA2) (Novus Biologicals, Centennial, CO), Smooth Muscle Myosin
Heavy Chain (SMMHC), Runt-related transcription factor (RUNX-2) (Santa Cruz
Biotechnology, Inc., Dallas, TX), Bone morphogenic factor-2 (BMP-2), Osteopontin
(OPN) (Rockland). Following primary antibody incubation, relevant secondary antibodies
were applied and signal was enhanced by ABC method (Vector, Burlingame, CA). Slides
were visualized by either 3,3´-Diaminobenzidine (DAB) or NovaRed peroxidase substrate
chromogens (Vector, Burlingame, CA) followed by a light hematoxylin counterstaining
prior to mounting.
Clariom S microarray analysis for differential gene expression
Total RNA (miRNAeasy Micro Kit, Qiagen) was prepared using aortas isolated
from adenine+hP and control group mice. Purified RNA was labeled with the help of a
GeneChip Wash and Stain Kit (Affymetrix, Santa Clara, CA), then hybridized to Clariom
S Mouse Array (Affymetrix, Santa Clara, CA) according to manufacturer instructions. Data
resulted in 22,206 detected probes that were used for subsequent analysis, and expression
patterns are displayed as a heat map.
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Statistics
All the results, including graphs in the figures, are given as mean±S.D. Statistical
analysis was performed using a one-way analysis of variance (ANOVA). Results were
considered to be significant when p-values ≤0.05. Tukey’s HSD was then used post-hoc to
identify the treatment groups with a significant difference.

Results
Body weights, serum biochemistry and histomorphology of kidneys
As a convention, mice fed the customized diets were monitored for loss of body
weight caused due to starvation, daily quantities of water consumed and urine excreted.
Mice fed the adenine containing diets lost weight at a steady rate (~20% over a period of 5
days) (Figure 6-2). To avoid death of animals due to starvation and weight loss [277, 278],
we modulated the feeding to allow for intermittent weight recovery when they reach 20%
weight loss before placing them back on the adenine diets. As with the rats, this allowed
us to eliminate mortality caused in mice due to this mode. Mice fed adenine-diets also were
observed to consume higher quantities of water and passed higher amounts of urine when
compared to the control diet-fed mice [279, 280] (data reported by animal housing facility
and not shown due to the requirement of metabolic cage usage). Biochemical analyses
performed on sera extracted from these mice suggest that severe dysfunction of kidneys is
induced in these mice with reported increases in Serum Creatinine (2-fold), Serum
Phosphorus (1.5-fold) and Blood Urea Nitrogen (BUN) levels (2.5 fold). (Table 6-1).
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In adenine-diet fed mice, discoloration and deformity of the kidneys were obvious
after 28 days of adenine feeding compared to the control mice (Figure 6-3A). Renal
histology in the adenine-diet fed mice shows deposition of crystalline structures in the
tubular lumen and peritubular inflammatory cell infiltration alongside several dilated
tubules (Figure 6-3 b1-b2). PAS staining showed dilated bowman’s spaces in some
glomeruli, tubular atrophy, and thickened basement membranes (Figure 6-3 b3-b4). Severe
tubulointerstitial fibrosis can be seen with Masson’s Trichrome stain (Figure 6-3 b5-b6).
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Figure 6-2: Body weights of the three groups of mice.
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Table 6-1: Serum biochemistry for renal function parameters in adenine-fed mice.
Control diet

Adenine diet

Serum Creatinine

<0.17

0.40±0.10*

Serum Phosphate

8.5±1.09

14.03±4.32*

Serum Calcium

9.02±0.19

8.42±1.68

BUN

19.6±3.2

49.43±12.74*

Glucose

198.2±27.01

141.83±56.19

GFR

>60

>60

* represents significant difference in adenine mice from control mice
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Figure 6-3: Morphology and histology of kidneys in mice. (A) Gross morphological
images of normal diet- and adenine diet-fed kidneys. (B) Histological staining of kidneys
in normal- and adenine diet-fed kidneys – H&E (b1-b2), Periodic acid-Schiff (b3-b4), and
Masson’s trichrome (b5-b6). (n=6 animals per group). Scale bar = 100µm.

In vivo Micro CT scanning for visualization of aortic calcification
Calcification of the aorta was evident on CT images of Ade+hP group mice. Threedimensionally scanned and reconstructed images visually confirmed presence of
calcification in the aorta, mainly in the infrarenal region (Figure 6-4 A1-A3). However, CT
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imaging performed on the same group of mice at their 28-day time point did not show any
tangible calcification (data not shown) while images from Ade+nP group mice were devoid
of any aortic calcification throughout the duration of the feeding (Figure 6-4 B1-B3), thus
confirming that 0.2% adenine feeding needs to be followed by 0.2% adenine + 1.8% P
feeding as described in literature. Control group mice also did not present any calcification
throughout the length of the study, as was expected (Figure 6-4 C1-C3). 3D models
fabricated using the CTAn software allowed us to color and visualize aortic calcification
in the Ade+hP group providing another in vivo assessment tool to track disease progression
(Figure 6-5).
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Figure 6-4: Representative images from in vivo 3D micro-computed tomography (Micro
CT) scanning and reconstruction. Coronal, sagittal and traverse sections from all the three
groups of mice are shown – Ade+hP (A1-A3), Ade+nP (B1-B3) and Control (C1-C3).
Calcification visualized on the reconstructed scans of Ade+hP is illustrated by red dotted
lines, arrows and circle in coronal, sagittal and transverse scan images respectively. (n=6
animals per group).
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Figure 6-5: 3D modeling of reconstructed mouse abdominal micro CT scans. Bone tissue
is pictured in white while possible aortic calcification in the Ade+hP group is colored in
red. (n=6 animals per group). Scale bar = 400µm.
Ultrasound imaging to monitor aortic calcification
Local PWV values were calculated using the distance between the two points in a
region of aorta divided by the transit time (Figure 6-6). Baseline PWVs in the three groups
did not differ from each other as was expected. No significant differences were seen in the
local PWVs at the 4 week feeding time point as well. However, following 4 weeks of high
P diet feeding, PWVs in the Ade+hP group (2.41±0.53 ms-1) were significantly higher than
in the Ade+nP (1.77±0.21 ms-1) and control groups (1.61±0.16 ms-1) (Figure 6-7 A-B).
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Figure 6–6: Local Pulse Wave Velocity (PWV) calculated as the distance traveled by the
pulse wave over transit time. (A) Colored Doppler and (B) Pulse-wave Doppler images
showing calculations of distance traveled and transit times respectively.
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Figure 6-7: Local PWV in the abdominal aortas of the three groups of mice. (A) Mean
Local PWV (ms-1) of Ade+hP, Ade+nP and Control groups at 0, 28 and 56 days of feeding.
(B) PWV (ms-1) of all the mice from Ade+hP, Ade+Np, and Control groups at 0, 28, and
56day time points. (n=6 animals per group) (*, p<0.05, One –way ANOVA with Tukey’s
HSD).
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Targeting of ELN-DiR-NPs to calcified regions of aortas
Elastin antibody conjugated and DiR dye loaded NPs (ELN-DiR-NPs) were
injected through tail veins of mice at the end of customized diet feeding. The NPs targeted
the calcified and degraded aortic elastic lamina sites within 24 hours while sparing the
healthy regions of the aorta in 4 out of 6 mice in the Ade+hP fed group injected with ELNDiR-NPs (Figure 6-8A a1), corresponding with the regions showing possible calcification
in both the Micro CT and Ultrasound images. Mice that were fed Ade+nP and control diets
did not show any targeting of the NPs to the aorta (Figure 6-8A a3, a5). Cross-sections of
aortas from Ade+hP fed mice show positive signal for Cy7 fluorescence confirming that
the ELN-DiR-NPs reached the calcified sites and targeted the degraded elastin fiber. No
fluorescent signal could be detected in aortic cross-sections from the remaining groups of
mice (Figure 6-8B).
Whole-mount aorta Alizarin Red staining
Images of whole mice aortas stained with alizarin red S and pictured on a
stereomicroscope show bright red spots for calcium on the aortas from the Ade+hP diet
group at the same regions where targeting was seen on the DiR fluorescence imaging
(Figure 6-8A a2). This indicates that the elastin in these aortic regions was degraded and
calcium was deposited, while the healthy regions did not show any staining for alizarin red.
No such bright stain spots were seen in aortas from either the Ade+nP fed group of mice
or control mice (Figure 6-8A a4, a6).
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Figure 6-8: Targeting of ELN-DiR-NPs and accumulation around calcified sites of the
aortas in Ade+hP mice. (A) DiR fluorescence as detected on iVIS Lumina imaging system
and whole-mount aorta alizarin red staining to indicate calcification. (B) Cross-sections of
aortas showing accumulation of ELN-DiR-NPs visualized by Cy7 fluorescence. (n=6
animals per group). Scale bar = 400µm.
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Histological analysis of aortic cross-sections
Representative histological sections of the aortas showed the presence of
calcification in the alizarin red-stained sections of Ade+hP fed mice (Figure 6-9 A). Black
deposits of calcium were observed under von Kossa staining (Figure 6-9 D), and elastin
fiber in the corresponding areas was damaged as shown by the VVG stain and Luna stain
images (Figure 6–9 G, J). On the other hand, calcification was totally absent in the Ade+nP
group (Figure 6-9 B, E, H, K) and control-diet fed mice aortic cross-sections. VVG and
Luna stain images from these two groups of mice showed that the elastin fiber remained
intact (Figure 6-9 C, F, I, L).
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Figure 6-9: Representative histological images of aortic cross-sections from Ade+hP diet,
Ade+nP diet and control diet-fed mice (n=6 per group). Alizarin Red S and von Kossa
staining showing calcification and calcium deposition in the media layer of Ade+hP mice.
Elastin fiber disruption and breakage as observed in VVG- and Luna- stained sections.
(n=6 animals per group), Scale bar = 100µm.
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Immunohistochemistry for VSMC-Osteogenic phenotypic switch
We performed immunohistochemistry to probe VSMC cell status after customized
diet feeding. Comparisons were made between the three groups – Ade+hP, Ade+nP, and
control – for expression of smooth muscle markers and osteogenic proteins. Staining for
SMC Actin showed that its expression is more or less uniform across the three treatment
groups, with somewhat lesser staining in Ade+hP and Ade+nP groups (Figure 6-10 A-C).
IHC staining for another smooth muscle marker, Myosin heavy chain 11 (SMMHC) did
not elicit any presence of the protein in both the adenine groups. However, its presence was
detected in the control group (Figure 6-10 D-F).
In addition to smooth muscle markers, we wanted to observe possible expression
of osteogenic markers in mice aortas. Specifically, we stained for RUNX-2 and BMP-2.
RUNX-2 expression in greatest in Ade+hP group, while it was not detected in either the
Ade+nP or control group (Figure 6-10 G-I). Similarly, the second osteogenic marker,
BMP-2, was also clearly identified in the Ade+hP group. BMP-2 staining was completely
absent in Ade+nP and control groups (Figure 6-10 J-L). Overall, IHC points towards the
phenotypic transformation of VSMCs in mice aortas from the Ade+hP group, as is
expected due to calcification.
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Figure 6-10: Immunohistochemistry for possible VSMC phenotypic transition to
osteoblast-like cells. Expression of two smooth muscle markers, SMC Actin, and SMC
Myosin is shown. Osteogenic markers RUNX-2 and BMP-2 are also shown in
representative micrographs pictured from all three groups of mice. (n=6 per group). (Brown
= DAB staining for SMC Actin and SMC Myosin, Red = NovaRed stain for RUNX-2 and
BMP-2, Blue = nuclei). Scale bar = 100 µm.
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Differential gene expression in isolated aortas
Among 22,206 analyzed gene expressions analyzed using the Mouse Clariom S
Array, 273 genes showing differential expression between Ade+hP and control groups
were identified with a cut-off fold change ≥ 2 or ≤ -2, and p < 0.05. Of the 273 genes with
differential expression, 163 showed up-regulation and 110 genes were down-regulated in
the Ade+hP group. Several genes known to be involved in calcification such as ALPL,
BMP2/4. Spp1, RUNX2, MSX2, etc. showed upregulation in the adenine+hP group, but the
fold change remained insignificant. VSMC-associated genes including Myh11, aSMA,
Tagln were downregulated but without any statistical significance.

Figure 6-11: Heat map of gene-level whole-transcriptome differential expression
profiling assay in Ade+hP diet- and control diet-fed groups of mice. (n=3 per group).
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Discussion
In the present study, we wanted to establish and validate the adenine-CKD model
in mice and achieve targeting of ELN-BSA-NPs to diseased (calcified) regions of the aorta
for further usage in calcification reversal and vascular health studies. Although we have
shown earlier that removal of elastin-specific vascular calcification by EDTA chelation
therapy is achieved in rat models of CaCl2 injury [259] and adenine model of CKD [281],
it is unclear if this removal is permanent and restores vascular homeostasis.
As with rats, established techniques to induced renal failure and its complications
in mice are mostly dependent on surgical intervention and/or transgenic manipulation [145,
162, 260, 282]. The adenine-induced CKD animal model again provides a viable
alternative due to its easy relative ease in implementation. However, the adenine model
does not consistently develop VC over time [262], owing partly due to the commonly used
C57BL/6J strain being quite tolerant of ectopic calcification [283]. A similar dosage of
adenine recommended in rats is next to impossible to implement in mice, as this level of
dosage (0.75% w/w) or even lower can prove lethal to mice within days [277]. Based on
some recent findings, 0.2% w/w seems to be a suitable dosage of adenine to induced CKD
in mice of C57BL/6J strain [277, 279].
In agreement with multiple reports of a strong association between VC and
phosphorus loading [275, 284-286], Tani et al. recently developed an adenine-based model
of CKD capable of producing MAC, without any genetic manipulations, surgical
interventions, or drug administration [287]. However, in our experience, reproducing their
model of adenine-based CKD and VC proved moderately successful. We surmise that this
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is due to inherent biological variation among animals themselves or the genetic strain used.
Recently, Yoshida et al. reported DBA/2 mice to be a suitable mouse model for the study
of MAC in CKD than C57BL/6J mice, which are thought to be calcification resistant [288].
Even so, during the course of this study, a few other studies have reported successful
induction of MAC in C57BL/6 mice via modifications of their own, either by altering the
route of adenine administration [289] or modification to the existing recommendations of
adenine feeding [290]. Based on our understanding of this model, the consistency and
severity of VC in this model still prove elusive. Further studies need to be pursued with
appropriate modifications and improvements to this model to attain a robust and stable
induction of MAC.
In our study with modifications to the model proposed by Tani et al., we
investigated targeting of NPs conjugated with elastin antibody to sites of aortic
calcification, developed in vivo imaging methodologies to monitor the onset and progress
of VC and further validated the model by probing VSMC transdifferentation and their
global gene expression profiles. A major hindrance of using noninvasive in vivo models of
vascular VC is the difficulty in monitoring the onset and progress of the disease. In our
study, we used high-resolution micro CT scanning and high-frequency ultrasound imaging
to produce images that can be used to analyze and quantify VC in the adenine-model of
CKD. Longitudinal micro CT scanning allowed us to detect the onset and presence of VC
in Ade+hP mice without the extended use of radiation or without injecting any contrast
agents. So far, studies to detect aortic calcium content using micro CT feature the use of
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contrast agents [291, 292] or employ transgenic mice models that take as long as 6-12
months to develop quantifiable calcification in the aortic tree [293, 294].
We measured PWV of the infrarenal regions of the aorta non-invasively as a
function of aortic distance and the transit time from Color-Doppler and Pulse-wave
Doppler-mode view windows to determine local aortic stiffness [295, 296]. This method
of PWV measurement is used ubiquitously in pre-clinical research, although it is used over
a larger length typically between the carotid and femoral arteries [297, 298]. As it happens
for carotid-femoral PWV evaluation in humans, this assessment is influenced by an error
in distance measurement even more so in mice due to the distance being ~10 times smaller
[299]. However, alternative methods to measure PWV are invasive with catheter-tip
pressure transducers placed in two different arteries to measure intra-arterial pressure and
transit times. An evident disadvantage with this approach is that the invasive procedure
may result in the death of the animal, which, in most cases, has to be dissected for exact
spatial distance measurement [299-301]. Our use of the simple, non-invasive method to
measure regional PWV gave us values ~2 ms-1, which are in agreement with literature [296,
302]. Green-LaGrange circumferential strain calculated from M-mode images serves to
further corroborate aortic stiffness caused due to VC in mice.
We demonstrated the reproducibility of our targeted nanoparticle delivery system
in this mouse model of adenine-CKD induced vascular calcification. Similar to our results
with rats, we observed no fluorescence emanating from aortas of control-diet fed mice or
in mice fed with 0.2% diet and normal levels of P (0.8%). When the P content in the 0.2%
adenine diet was switched up to 1.8% after initial induction of renal failure, the aortas
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clearly showed targeting of our NPs carrying DiR. Even in these mice, healthy regions of
the aorta with uncalcified and undamaged elastin did not show any detectable fluorescence,
confirming that the elastin antibody conjugated NPs only target diseased regions of the
aortas. Cross-sections of these aortas further validate our findings by ratifying that the
ELN-DiR-NPs infiltrate the medial layers of the diseased aorta through the vasa vasorum.
Our targeted delivery system can, therefore, be used to deliver any therapeutic to damaged
elastin and calcified sites in these mice.
Micrographs taken from histological staining of mouse aortas show clear evidence
of MAC exclusively. Elastic fiber layers in these calcified areas appeared to be disrupted
and broken around areas of calcium deposition, which is a characteristic feature of MAC.
Immunohistochemical staining for presence of common smooth muscle markers, α-SMC
actin, and SMMHC, was done to observe phenotypic alteration in VSMCs. α-SMC actin
was found to be expressed evenly across the three groups, whereas SMMHC staining was
lower in both the adenine-fed groups. Parallelly, we also detected positive staining for both
osteogenic markers, RUNX-2 and BMP-2, in the Ade+hP group. No expression for either
was seen in either the Ade+nP group or control group. This suggests a phenotypic switch
of VSMCs associated with calcification in the Ade+hP group. Differential gene expression
profiles obtained by Clariom S Arrays showed that 163 genes were upregulated in the
Ade+hP group. Genes known to be involved in calcification and VSMC phenotypic switch
to osteoblast-like phenotype such as ALPL, BMP2/4, Spp1, Igf1, MSX2, RUNX2, etc.,
although upregulated, did not show significant fold change difference. Genes associated
with VSMCs namely Myh11, aSMA, Tagln, and others showed slight downregulated

123

compared to the control group. However, the increase or decrease in expression of both
osteogenic- and VSMC-associated genes were not statistically significant. Further
experiments with higher sample size and analyses are needed to draw more informative
conclusions from gene expression profiles.
In conclusion, we were able to establish the adenine-induced CKD model of
calcification in a commonly used C57BL/6J strain of mice. Usage of small animal imaging
techniques viz., high-resolution microCT scanning, and high-frequency ultrasound
imaging help us to monitor the progress of VC and gauge aortic stiffness parameters in
these mice in vivo. We successfully demonstrated that our NP delivery system is able to
target diseased regions in the aortas of mice with calcified aortas. Further validation of the
model confirms that there is a transdifferentation of VSMCs to an osteogenic phenotype
happening in the event of VC in the aorta. This model of adenine-induced CKD model of
VC will allow us to test our targeted chelation therapy with EDTA NPs through monitoring
and quantification of calcification in vivo and to investigate whether its reversal will result
in restoration of healthy VSMC status, thus improving vascular function.
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SPECIFIC AIM 4

TO DEVELOP AN EX VIVO PORCINE CAROTID ARTERY ORGAN CULTURE
MODEL OF VASCULAR CALCIFICATION FOR EVALUATING WHETHER
TREATMENT WITH EDTA LOADED NANOPARTICLES CONJUGATED WITH
AN ANTI-ELASTIN ANTIBODY ELIMINATES CALCIFICATION AND
REVERTS VSMCs TO THEIR NORMAL PHENOTYPE

Introduction
Vascular calcification (VC) is now considered an active and complex process
resembling developmental skeletal formation. In addition to key events required for
initiation and propagation of VC, such as loss of inhibitor function, upsurge of calcification
promoters, development of calcifiable extracellular matrix (ECM) with degradation of
elastin laminae due to inflammatory enzymes, and osteogenic differentiation of vascular
smooth muscle cells (VSMCs) accompanying apoptosis and vesicle release. The latter two
are key mechanisms that may occur simultaneously. There is a longstanding debate
regarding which process occurs first, whether adoption of an osteoblast-like phenotype by
VSMCs leads to or results from elastin damage and calcification [303]. We have evidence
to believe that elastin degradation and mineralization occurs first, which triggers VSMCosteoblast-like cell phenotypic shift [273, 274]. We further hypothesize that
demineralization of calcified arteries promotes restoration of homeostasis.
Calcifying vascular cells have been known to share properties with bone, including
higher alkaline phosphatase (ALP) activity, osteocalcin (OCN) and osteopontin (OPN)
expression and increased presence of the bone morphogenic protein (BMP) family [304,
305]. A number of studies have focused on understanding the underlying process of VC
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through in vitro models of primary cell lines from mice [306], bovine [307], and human
cells [275, 308]. Usage of monocultures allows for better control of initial experimental
conditions to improve detection accuracy. However, morphological variation has been
noted at higher passage numbers, and beyond that, gene phenotype of VSMCs is altered.
Moreover, a 2D cell culture cannot correctly examine the influence of cell-cell interaction.
Therefore, in this present aim, we hypothesize that an organ culture model would
provide useful information to bridge the gap between monolayer cultures and animal
models in vogue. Since our terminal goal is to transition our EDTA chelation therapy from
present small animal models to human application, we presumed that an ex vivo organ
culture from a larger animal would provide a feasible culture condition for assessment of
VC, and VSMC cell status before and after demineralization. Here, we propose a porcine
carotid artery organ culture model of VC under Pi-stimulation.
Materials and Methods
Isolation and collection of porcine carotid arteries
Fresh porcine carotid arteries were harvested from female domestic crossbred pigs with a
Yorkshire background in Godley-Snell Research Center (Clemson, SC) for this study. All
animals were 3-4 months old and weighed 35-45 kg. After the pigs were euthanized using
commercial euthanasia solution, the thyroid cartilage was located. A 10 cm incision was
made 3 cm laterally to the thyroid cartilage using a 10-blade scalpel, extending 5 cm
superiorly to the thyroid cartilage and 5 cm inferiorly to the thyroid cartilage. Curved Mayo
scissors were used to dissect through the underlying fascia and expose the sternocephalic
muscle. The sternocephalic muscle was retracted to expose the internal and external jugular
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veins, the common carotid artery, and the vagus nerve. The carotid sheath was dissected
using a 10-blade scalpel, and the carotid artery was isolated and removed using surgical
scissors. Following excision, the arteries were placed in sterile Moscona’s solution (8 g
NaCl, 0.2 g KCl, 1 g NaHCO3, 1.7 g glucose, 0.005 g NaH2PO4 in 1 L DI water; pH 7.2)
on ice and transported back to the lab.
Organ culture of porcine carotid arteries
A day before tissue collection, under sterile conditions, the bottom surface of each
well in 12 well plates was coated with 2% agarose. Once the agarose hardened, sterile basal
medium was added to each well (DMEM with 4500 mg/mL glucose), and well plates were
incubated at 37°C overnight to equilibrate the agarose. On the day of tissue harvest, the old
medium was replaced with fresh basal medium, and equilibration was continued until the
tissues were ready. The collected carotid arteries were washed well in cold, sterile PBS
supplemented with 1-3% Penicillin/Streptomycin, to remove remnants of blood, and the
surrounding tissues were carefully cleaned with sterile, blunt forceps. Carotid arteries were
then cut into rings of 1-2 mm in length and washed in cold, sterile PBS. Artery rings were
placed individually in the pre-incubated and pre-equilibrated 12 well plates. Basal medium
was now replaced with complete culture medium (DMEM with 4500 mg/mL glucose
supplemented with 15% FBS, 1% Penicillin/Streptomycin). To induce calcification, Pi
(Na2H2PO4/NaH2PO4 at pH 7.4) was added the supplemented DMEM at a high
concentration of 2.6mM in half of the total wells. The culture medium, both control and
calcification media, was changed every 2 days. The culture went on for 1, 3, and 7 days
followed by treatment with n=5 for each time point. An example well plate is outlined in
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Figure 7-1. Tissues were cultured in individual well plates for histology, protein, and RNA
isolation at each time point, respectively.

Figure 7-1: Sample well plate of porcine carotid artery organ culture. Blue designates
wells with control culture medium. Wells containing medium supplemented with Pi to
induce calcification are pictured in red. (n=5 per time point per study).
Treatment of porcine carotid rings with EDTA NPs for ex vivo
chelation therapy
Following induction of calcification at Day 7, carotid artery rings were treated with
nanoparticles (NPs) loaded with EDTA and conjugated with an anti-elastin antibody (ELNEDTA-NPs) to examine for possible reversal of calcification. After aspirating media and
washing the tissues with sterile PBS, NPs were applied directly on the tissue rings (at a
final concentration of 10 mg EDTA per well) using a micropipette and allowed to conjugate
for a short time. Media was replenished immediately afterwards to continue the culture.
NPs without any EDTA loaded, but conjugated with the anti-elastin antibody were used

128

for non-EDTA control group (ELN-Blank-NPs). A third of group of wells were not treated
with any NPs to act as non-treatment controls. The tissues were treated as described above
for two times every 3 days over one week.
Histological staining of carotid artery rings
At Day 1, 3 and 7, the carotid artery rings consigned to undergo histological
analyses were taken out from their respective well plates and fixed in 10% neutral buffered
formalin for 24 hours. Following processing for removal of formalin, the rings were
embedded in paraffin and sectioned at 6µm thickness and stained with the following
histological stains for tissue morphology – Hematoxylin & Eosin (H&E), Verhoeff von
Geison (VVG), Alizarin Red S, von Kossa, Luna staining for elastin fibers.
Immunohistochemical analyses for expression of osteogenic markers
Briefly, rehydrated paraffin sections (5 μm) were exposed to a boiling water bath
in a pressure cooker for 10 minutes with citrate buffer (10 mM Sodium Citrate, 0.05%
Tween 20, pH 6.0) for heat-induced unmasking of antigens. Endogenous peroxidases were
quenched with 3% hydrogen peroxide. Tissue sections were incubated in normal serum for
1hr at RT to block out non-specific binding. Primary Antibodies against were applied
overnight at 4°C against Alpha smooth muscle actin (ACTA2, or SMC actin) (Novus
Biologicals, Centennial, CO), Smooth Muscle Myosin Heavy Chain (MYH11, or
SMMHC), Runt-related transcription factor (RUNX-2) (Santa Cruz Biotechnology, Inc.,
Dallas, TX), Bone morphogenic factor-2 (BMP-2). Following primary antibody
incubation, relevant secondary antibodies were applied, and signal was enhanced by ABC
method (Vector, Burlingame, CA). Slides were visualized by either 3,3´-Diaminobenzidine
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(DAB) or NovaRed peroxidase substrate chromogens (Vector, Burlingame, CA) followed
by a light hematoxylin counterstaining prior to mounting.
Quantification of calcium in tissue rings
Following being harvested and washed with PBS, the aortic rings were treated with
0.6 N HCl overnight at 4°C to decalcify and release bound Ca into the supernatant. Dissolve
calcium in the supernatants was determined by the o-Cresolphthalein method using a
commercially available kit (Abcam Inc., Cambridge, MA). This method is based on Ca
reacting with o-Cresolphthalein complexone in an alkaline solution. Ca concentrations
were reported after being normalized to dry weights.
Total protein extraction from carotid cultures
Carotid artery rings were collected at each time point for protein extraction, snapfrozen, and stored at -80°C until extraction. Frozen tissue rings were pulverized with precooled mortar and pestle and placed in pre-cooled 1.5mL centrifuge tubes containing
600µL RIPA buffer (23 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% Triton X100, 1% sodium deoxycholate, 0.1% SDS substituted with protease inhibitors at the time
of use). Vortex well and homogenize the tissue completely using probe sonication. The
tubes were then shaken on ice for approximately 3 hours, and proteins were extracted by
centrifugation @12000rpm at 4°C for 20 minutes. The resulting supernatants were
carefully transferred to fresh, precooled 1.5mL tubes using a micropipette and stored at 20°C for further analyses. BCA protein assay was performed on the final samples to
determine the protein concentration.
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Western Blotting
Samples containing equal amounts of protein, as measured from protein
quantification, were mixed with 4X reducing buffer containing β-mercaptoethanol, boiled
down 5 minutes and cooled. They were then subjected to sodium dodecyl sulfatepolyacrylamide electrophoresis with Tris/Glycine denaturing running buffer (25 mM Tris,
192 mM Glycine, 0.1% SDS) for 50 minutes at 200V on 4-15% Mini-Protean TGX precast
gels (BioRad Laboratories Inc., Herculus, CA). The gels were subsequently transferred to
pre-conditioned polyvinyl fluoride (PVDF) membrane. The transfer lasted for 50 minutes
at 100V in a tank system on ice, using Tris/Glycine transfer buffer (25 mM Tris, 192 mM
Glycine, 20% methanol). After washing with TBS and blocking for 1 hour at RT using
10% non-fat dry milk in TBS, the membrane was washed in TBST (0.05% Tween in TBS)
3 times for 5 minutes each. The membrane was then incubated overnight at 4°C with
primary antibodies in 2% dry milk in TBST. The following primary antibodies were used:
Alpha smooth muscle actin (ACTA2, or SMC actin, 1:10000) (Novus Biologicals,
Centennial, CO), Smooth Muscle Myosin Heavy Chain (MYH11, or SMMHC, 1:3000)
(Proteintech Group Inc., Rosemont, IL), Runt-related transcription factor (RUNX-2, 1:500)
(Santa Cruz Biotechnology Inc., Dallas, TX), and Bone morphogenic factor-2 (BMP-2,
1:2000) (Proteintech Group Inc., Rosemont, IL). GAPDH (1:1500) (Proteintech Group
Inc., Rosemont, IL) and β-actin (1:1000) (Santa Cruz Biotechnology Inc., Dallas, TX). The
next day, the membrane was washed 5 times for 10 minutes in TBST to remove the
unbound primary antibody and incubated with an appropriate HRP-conjugated secondary
antibody (1:20000) in 2% dry milk in TBST for 1 hr at RT. After washing with TBST for
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3 times 10 minutes each time, the membrane was developing using Clarity Western ECL
Substrate (BioRad Laboratories Inc., Herculus, CA) for 5 minutes. Membranes were then
imaged using Chemi Doc It2 imaging system (UVP) at different exposure times for
individual proteins. Densitometry analysis was performed using Image J software for
quantification.

Results
Histology of porcine carotid artery rings
Hematoxylin & Eosin staining of formalin-fixed and paraffin-embedded carotid
ring sections show appreciable staining for nuclei until Day 3 of the organ culture in the
calcified group alluding to cellular presence. Only on Day 7, there is a noticeable decrease
in nuclear staining (Figure 7-2 B-D). Images from the control group suggest that the cells
are thriving throughout the duration (Figure 7-2 A). Luna stain and VVG stain were used
to observe elastin fiber morphology. There is no discernible damage to elastin seen in the
calcified group in any of the Day 1, Day 3 or Day 7-time points, either on the Luna stained
sections (Figure 7-2 F-H) or VVG sections (Figure 7-2 J-L). As expected, intact elastin
fiber was identified in the control group (Figure 7-2 E, I).
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Figure 7-2: Digital micrographs of H&E, Luna, and VVG staining on porcine carotid
rings. (A-D) H&E staining shows. (E-H) Luna stain illustrates intact elastin fiber structure
with no obvious damage. (I-L) VVG Stain for elastin fiber confirms observations made on
Luna stain images. (n=5 per time point per group). Scale bar = 200 µm.

Evaluation of calcification of the carotid arteries
Alizarin Red S staining was performed to evaluate calcium deposition. Following
incubation of the carotid arteries with calcification medium, faint deposition of calcium is
observed as early as Day 1 of the organ culture (Figure 7-3 B).
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Figure 7-3: Evaluation of calcification by histological staining of carotid artery rings.
Representative images of calcification in porcine carotid artery cross-sections as pictured
by Alizarin Red S stain (A-D) and von Kossa Stain (E-G) (n=5 per time point per group).
Scale bar = 200 µm.

Calcium deposition increases as the culture progresses at Day 3, and by Day 7, heavy
calcification of the carotids was seen microscopically (Figure 7-3 C-D). von Kossa staining
confirms the presence of calcium deposits with increasing deposition from Day 1 through
Day 7 (Figure 7-3 F-H). No calcification or calcium deposits are observed in the carotid
arteries incubated with control medium (Figure 7-3 A, E).
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Immunohistochemistry for smooth muscle cell apoptosis and smooth
muscle marker expression
Immunohistochemistry for Caspase-3 shows considerable expression of the
apoptotic protein across control and calcified groups. At Day 1, 3, and 7 in the calcified
arteries, Caspase-3 is present in all the three layers of the arterial wall (Figure 7-4 A-D).
Staining for SMC actin is comparable in the control group, and at all the three-time points
in calcified arteries, indicating that there may not be a reduced expression, as expected,
with increasing calcification (Figure 7-4 E-H). SMMHC was fairly well expressed in the
control group. Calcified group shows a negligible signal for SMMHC on Day 1 and 3,
whereas its expression was detected at Day 7 (Figure 7-4 I-L). Overall, smooth muscle cell
apoptosis is consistent in both control and calcified arteries; Expression of SMC actin was
not found to decrease over time with increased deposition of Ca in the calcified arteries.
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Figure 7-4: Immunohistochemical staining for smooth muscle apoptosis and expression of
smooth muscle markers. Representative images of calcification in porcine carotid artery
cross-sections from Caspase-3 (A-D), ACTA2 (E-H), and SMMHC (I-L) staining. (n=5
per time point per group). (Brown = DAB, purple = nuclei). Scale bar = 200 µm.
Immunohistochemistry for expression of osteogenic cell markers
Following analysis of smooth muscle cell apoptosis and expression of smooth
muscle cell markers, we wanted to observe for possible upregulation in osteogenic cell
markers. As seen in Figure 7-5, there was very sparse, if any, expression of both RUNX-2
(B-D) and BMP-2 (F-H) in the calcified group at Day 1, 3 and 7-time points. Only on Day
7, RUNX-2 could be detected in calcified group. Control group did not show any staining
for the two osteogenic markers, which was expected (A-E).
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Based on observations made with IHC staining, VSMCs in the carotid artery
cultures seem to undergo apoptosis both in the control and calcified groups. There was no
significant reduction of smooth muscle cell marker expression or upturn in osteogenic
marker expression in the calcified group.

Figure 7-5: Immunohistochemical staining for osteogenic markers – RUNX2 and BMP2.
Representative micrographs of IHC staining for RUNX-2 (A-D), and BMP-2 (E-H) in
control and calcified groups. (n=5 per time point per group). (Red = NovaRed, purple =
nuclei). Scale bar = 200 µm.

Western blot analysis for smooth muscle and osteogenic markers
Western blotting was used to check for expression of smooth muscle- and
osteogenic- markers on total protein isolated from both the groups of carotid artery rings.
α-SMA expression was normalized to GADPH housekeeping gene, and β-actin was used
to show relative SM-MHC expression. At Day 1 and Day 7-time points of culture, no
significant increase or decrease was observed in the expression of the two smooth muscle
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proteins in the calcified group when compared to controls (Figure 7-6), consolidating the
observations made with immunohistochemistry. At any of the time points, no bands could
be detected for either of the two osteogenic markers. Both RUNX-2 and BMP-2 did not
show any expression in control and calcified groups (Figure 7-7).

Figure 7-6: Western blots for smooth muscle cell markers in control and calcified carotid
artery rings. (A, B) α-SMA expression in control and calcified carotid aortic rings. No
significant difference is seen in expression at either Day 1 or Day 7-time points. (C, D)
SM-MYH expression in control and calcified carotids. As with α-SMA, there was no
statistically significant difference in expression at both time points. (n=4 per group per time
point) (White columns: control group, black columns: calcified group).
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Figure 7-7: Images taken after western blotting for osteogenic markers in control and
calcified groups. No expression could be detected for the two osteogenic markers tested –
RUNX-2 and BMP-2 – at any time point in either control or calcified carotid rings. (n=4
per time point per group). (Red arrow indicates positive control for RUNX-2; white arrow
shows protein ladder).
Reversal of Pi-induced calcification with EDTA-loaded NP treatment
Treatment with ELN-EDTA-NPs moderately reversed calcification induced by
supplementation with Pi. Alizarin red staining of carotid artery rings following treatment
shows modest reversal of calcification in the ELN-EDTA-NPs group while bright red
calcified areas persevered in the ELN-Blank-NPs group and the untreated group (Figure 78 A-C). Similar results were witnessed with von Kossa staining, with ELN-EDTA-NPs
staining least for Ca deposits where as both the ELN-Blank-NPs group and untreated
groups had extensive staining (Figure 7-8 D-F). Tissue rings were decalcified by incubation
in 0.6N HCl and Ca in the supernatants was quantified using o-Cresolphthalein
complexone method for detection of Ca. Quantified Ca was normalized to dry weights of
the tissues with ELN-EDTA-NPs group having mean quantified Ca values of 0.97±0.30
µg/mg of dry weight. Ca values in ELN-Blank-NPs and untreated groups remained at
1.39±0.09 and 1.42±0.34 µg/mg of dry weight of tissue respectively. It is pertinent to note
here that not all the tissues in ELN-EDTA-NPs showed reversal of calcification and the
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difference remained statistically insignificant (Figure 7-9), probably due to the small
number of samples tested (n=3).

Figure 7-8: Representative histological images of carotid artery rings depicting
calcification after treatment. ELN-EDTA-NPs show reasonable reversal of calcification
while persisting in ELN-Blank-NPs and untreated groups. (n=3 per group) Scale bar = 200
µm.
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Figure 7-9: Quantification of Ca by o-Cresolphthalein complexone method following
treatment. ELN-EDTA-NPs suggest removal of calcification in 2 out of 3 tissue samples
used. ELN-Blank-NPs and untreated groups have comparatively higher levels of Ca. (n=3
per group).
Discussion
In the present study, we utilized the well-known Pi-induced model of calcification
in organ culture of porcine carotid arteries for the first time. This experimental model of
carotid artery culture is relatively simple and easy and cuts down the time to thoroughly
evaluate the process of induction and reversal of VC.
We followed an ex vivo organ culture model described in previous reports [309] to
generate a high-phosphorus-induced VC [310-313]. Many such studies report that a
concentration of 2.6-3.0 mM Pi in the culture media as it produces a degree of calcification
easy to detect through examination under microscopy. However, these studies utilize
VSMCs from humans, rats, and mice and aortic rings from rats and mice for their culture
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studies. For our study, we used porcine carotid arteries harvested fresh from swines at the
local animal research facility. Pi-induced calcification has not been studied in porcine
artery cultures hitherto, and we believe this will serve as an ideal model to explore VC and
chelation therapy, towards larger animal studies in vivo.
Following exposure to extracellular Pi in the media, carotid artery rings undergo
time-dependent calcific deposition with increasing deposition up to 7 days in culture, as
reported in similar studies with other tissues mentioned above. Though, no accompanying
elastin fiber degradation or destruction was readily apparent in either Luna stained sections
or VVG staining [314, 315]. Beyond 7 days, there was no apparent increase in calcification
under microscopic observations on histological stains (data not shown). Hence, we chose
the Day 7-time point for our reversal experiments.
Next, evaluated VSMCs for possible reprogramming into osteoblast-like cells
through immunohistochemistry, western blotting, and gene expression analyses. Cultured
SMCs have long been known to be capable of calcifying and expressing osteogenic
phenotypes when exposed to high levels of Pi [95, 309, 316, 317]. In our assessment for
phenotypic change of VSMCs into osteoblast-like cells, we found no upregulation of
RUNX-2 and BMP-2, both markers are known to be expressed by calcifying vascular cells.
IHC staining for the two osteogenic markers does not show any enhanced staining in
calcified carotid rings. While VSMCs in cultured rings show expression of the apoptotic
marker Caspase-3 [318], its presence is universal amongst control and calcified groups.
Simultaneously, there is no loss of smooth muscle cell markers, α-SMC actin, and
SMMHC, with time-dependent increase in calcium deposition.
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Immunoblot analyses for increased protein expression of RUNX-2 and BMP-2
showed no detection for either of the two osteogenic markers in the calcified group, on Day
1 or Day 7-time points. Even after repeated experiments with different concentrations of
primary antibodies and higher quantities of total proteins loaded for gel electrophoresis, no
bands could be visualized. Concomitantly, expression of α-SMC actin and SMMHC
remained fairly constant over the 7-day time period with no statistically significant
difference between the control and calcified groups. Put together, our data with IHC and
WB reveals that calcification of the carotid artery rings in this setting maybe due to passive
mineralization and does not involve any cellular responses.
We further assessed whether treatment with EDTA-loaded NPs conjugated with an
anti-elastin antibody could reverse the Pi-induced calcification in carotid tissue rings. We
applied EDTA-loaded NPs at a final dosage of 10 mg EDTA/well, twice over a period of
one week. Histological staining with alizarin red and von Kossa stains to spot calcification
following treatment suggest that there is some degree of reversal of calcification with ELNEDTA-NPs, while calcification persisted in the tissue sections from ELN-Blank-NPs and
untreated groups. To measure the Ca present in tissues after treatment, we decalcified the
carotid rings by placing them in 0.6N HCl [319] and determined the Ca released into the
supernatant using the o-Cresolphthalein method. The observations we made with histology
were corroborated with quantified Ca values being noticeably lower in the ELN-EDTANPs group compared to the others. However, out of the three tissue samples used to analyze
reversal of calcification, only two show lessened calcium. ELN-EDTA-NPs show
promising results, but the change is not significant. This observation could have been due
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to the small number of samples used (n=3), and the results did not reach statistical
significance. To substantiate this hypothesis, a pilot study with increasing amounts of
EDTA directly added to the media yielded no removal of calcification. Further, the dosage
of ELN-EDTA-NPs at 10mg/well may not have been sufficient to achieve complete
reversal. Higher magnitudes of EDTA targeted to calcific deposits may be needed to
achieve better removal, although EDTA is known to be cytotoxic.
We conclude that exposure to excess Pi concentrations in the culture media resulted
in time-dependent increase in mineralization of calcium deposits in porcine carotid artery
rings. Evidence from immunohistochemical staining and western blot analysis for smooth
muscle and osteogenic markers reveals that there was no significant reduction in expression
of the former, combined with no increase in bone protein expression at any of the threetime points. Treatment with ELN-EDTA-NPs moderately removed mineralization from
calcified tissue rings. At this point, the ex vivo porcine carotid artery organ culture of Piinduced VC is not optimized for use in studies to assess effects of EDTA chelation therapy
on VSMC calcification and transdifferentiation. Further experiments are necessary to
improve the model to represent the process of active calcification that occurs in vivo.
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8

CONCLUSIONS AND FUTURE RECOMMENDATIONS

Conclusions
Vascular calcification (VC) is a key pathological feature observed in various forms
of cardiovascular diseases. It is commonly seen in aging, diabetes, and chronic kidney
disease (CKD). Elastin-specific medial arterial calcification (MAC) is more commonly
seen in CKD, and patients with CKD are more prone to die of a cardiovascular event due
to MAC than fully progress to complete renal failure. Majority of the current treatment
methods are focused on curtailing the causative factors and preventing calcification. A
novel therapeutic strategy that stabilizes and eventually reverses calcification is an urgent
health care need and is of immense value to patients with CKD. We have developed
nanoparticles that can be targeted to the sites of arterial calcification by using an antibody
that exclusively recognizes and binds to degraded elastin, a common appearance in
calcification. Our goal is to load these nanoparticles (NPs) with Ethylene diamine
tetraacetic acid (EDTA), a well-known chelating agent and deliver EDTA to the calcified
sites on the aorta to facilitate reversal of mineralization without causing any unpleasant
side effects.
In the first part of this project, we set out to test our targeted EDTA chelation
therapy in a clinically relevant systemic model of CKD-related calcification. For this, we
used the well-known rat adenine-induced CKD model of medial calcification. We
established this model without unexpected mortality, as is usually seen, and fairly evenly
produced calcification across all animals. Then, we demonstrated the ability of our NPs to
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target calcified sites on the aortas of these rats. We were able to successfully reverse
mineralized calcium in vivo by site-specifically delivering EDTA at a dosage ~twenty-fold
lower than systemic chelation therapies currently in use. This was achieved without causing
any unwanted side effects, and the animals showed signs of improvement in vascular
function.
Subsequently, we replicated targeting of NPs to calcified sites in a murine model
of CKD-related calcification. This was accomplished in adenine plus high phosphate
induced model of CKD and medial calcification. We further wanted to establish ways to
monitor disease progression in vivo for forthcoming investigations on reversal of
calcification and its effect on disease outcomes and vascular health. For this, we used small
animal imaging techniques such as ion micro CT and ultrasound to visualize onset and
development of calcification. One of our eventual objectives is to explore phenotypic
changes in VSMCs prior to and after reversal of calcification in vivo. Stringent cell lineage
tracing studies on VSMCs will be required to probe their fate, and we laid down the first
step by profiling global gene expression of VSMCs in calcified aortas of the adenine-diet
fed mice.
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Recommendations for future work
1) Despite the successful use of adenine model to evaluate chelation therapy in
reversal of MAC, this model presents high biological variability with regards to
development of robust calcification. In humans, calcification is seen throughout
the length of the aortic tree, and in heart valves as well. In our experience with
the adenine model, both in rats and mice, calcification in these animals was
restricted to infrarenal region of the aorta. Keeping in consideration studies
showing calcification at various loci on the aorta, we have only had moderate
success in establishing severe MAC at different sites on the vasculature.
Additionally, all the animals used in this model do not show calcified deposits;
only as many as 60% of the animals develop MAC. Put together; it would require
an unusually high number of animals to investigate and compare treatment
regimens with acceptable statistical power. It is essential to make further
adjustments to the model we used, not restricted to dietary alterations, and usage
of a genetic strain of mice more prone to calcification.
2) At this time, we do not know if the VSMCs return to their original phenotype
after reversal of calcification in vivo, or if they undergo apoptosis and are
repopulated by new SMCs recruited from surrounding cells, pericytes,
endothelial-mesenchymal transition (EndoMT), or hematopoietic stem cells
(HSC). Lineage tracing studies need to be performed with tamoxifen-induced Cre
recombinase mice with dual fluorescence indicator/reporter for SMC, EndoMT,
HSC, or pericyte origin.
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3) The groundbreaking nanoparticle delivery system alone could be used to deliver
not just chelating agents, but other specific drugs, proteins, or imaging agents to
the calcified sites, and could open a host of possibilities. For example, the targeted
delivery system could be utilized to deliver pentagalloyl glucose (PGG) to the
damaged elastin sites. PGG tightly binds to elastin and blocks its calcium-binding
sites, while also helping in reduced expression of matrix-degrading enzymes and
osteogenic proteins, in addition to replenishing elastin fiber deposition.
4) Patients with CKD need dialysis as their kidney function worsens and GFR falls
below 15. As mentioned, the long term goal of this project is to translate our
targeted EDTA chelation to individuals suffering from kidney disease and
improve their cardiovascular outcomes. It would, therefore, be judicious to
administer targeted EDTA chelation to the patients at the time of dialysis as a cotherapy, to avoid repeated incisions. Currently, each dialysis treatment lasts about
four hours and is done three times per week. At this stage, our NPs are designed
to release EDTA in a burst release manner over a period of 72 hours. This would
mean that patients need to be given intravenous injections at a rate of two times
per week if the targeted EDTA chelation regimen is endorsed. Accordingly, it is
recommended that further tailoring of the NPs is necessary to ensure that the
chelating agent is released quicker, within 48-72 hours, to ensure that co-therapy
with dialysis remains a possibility.
5) Different mineral phases arise during uremic MAC due to the result of different
pathological mechanisms involved in their precipitation. Hydroxyapatite
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[Ca10(PO4)6OH2], a common skeletal mineral was reported in uremic arterial
calcifications in some studies [320, 321]. In another study, a combination of
brushite and hydroxyapatite were observed in calcifications of stenotic
arteriovenous fistulas [322]. A study of uremic calcification in rodents detected
the presence of whitlockite [(Ca, Mg)3(PO4)2], along with hydroxyapatite [323].
Recently, whitlockite was identified in human uremic arterial calcifications. This
is in contrast to most studies, which so far have reported only hydroxyapatite or
carbonated apatite in uremic vascular calcifications [322]. It would then be
imperative to properly characterize the kind of mineral deposition present in the
calcified aortas of patients with CKD as this would affect the choice of chelating
agents for dissolution of mineral.
6) Considering the value of in vivo imaging and monitoring of disease progression
in impending studies in mice, it would be useful to have another diagnostic tool
using CT imaging with gold as X-ray contrast. Currently, we relied on CT
scanning without the use of any contrast agents for improved visibility of
calcification. Recently, our lab has evinced that gold NPs, combined with the
elastin targeting approach, can be used to predict the degree of elastin damage
and rupture potential in AAAs [324]. A quantitative relationship may thus be
established to correlate elastin damage at calcified sites and corresponding gold
nanoparticle binding, providing us an additional remarkable visual tool to track
development of calcification in mice before, and after EDTA chelation therapy.
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7) Arterial calcification is augmented in metabolic syndrome, type 2, and type 1
diabetes mellitus, resulting in impaired vessel compliance and function.
Consequences of MAC in diabetes are impaired hemodynamic regulation and
increased cardiac post-load; it is a strong predictor of lower-extremity amputation
and mortality. Patients with type 2 diabetes were at a four-fold increased risk for
lower-extremity amputation and two-fold enhancement of cardiovascular
mortality [325, 326]. Use of site-specific chelation therapy for reversal of diabetic
MAC and improvement in arterial health is thus an attractive prospect.
8) Our nanoparticle targeting system is a product of several years of successful
substantiation in various ex vivo and in vivo small animal models. To utilize this
approach for targeting of damaged elastin in other pathologies such as Marfan
syndrome, varicose veins, deep vein thrombosis, cutis laxa, Pseudoxanthoma
elasticum (PXE), etc. can result in fresh drug delivery strategies. Additionally,
nanoparticle surfaces could be modified to target established markers to specific
cancers [327, 328].
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